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Sulfotransferases (SULTs) belong to one of the major families of phase II drug 
metabolism enzymes (Coughtrie 2002). They catalyze the transfer of a sulfuyl group to 
hydroxyl-containing molecules.   
 
ROH + PAPS          R-OSO3H + PAP  
 
The co-substrate for all SULTs is 3′-phosphoadenosine 5′- phosphosulfate 
(PAPS). Sulfation (sulfuryl transfer) is widely observed in various biological processes. 
Various biological signaling molecules, including hormones, neurotransmitters, peptides 
and proteins, can be sulfated. Depending whether they are soluble or not, SULTs can be 
classified into membrane-associated or cytosolic SULT (Strott 2002). The membrane 
associated SULTs sulfate large molecules including carbohydrate, peptide, and protein. 
They are mainly related with posttranslational modification of carbohydrates, peptides, 
and proteins. The addition of a sulfonate group to carbohydrates can transform a common 
structural motif of a carbohydrate into a unique recognition site for a specific receptor 
(Hooper, Manzella et al. 1996). For many proteins, tyrosine sulfonation is important for 
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biological activity and correct cellular processing (Vishnuvardhan and Beinfeld 2000). 
The cytosolic SULTs sulfate small molecules such as hydroxyl-containing xenobiotics, 
steroids, bioamines and therapeutic drugs. The substrate specificities of cytosolic SULTs 
are very broad. Most hydroxyl-containing compounds (phenols and alcohols) are 
substrates for one of the SULT isoforms. Sulfation can change biological functions of 
endogenous signaling molecules because  the sulfated molecules are usually unable to 
bind to their receptors and become inactive (Roy, Lavrovsky et al. 1999). For instance, 
the genomic action of steroid hormones is inhibited by sulfoconjugation because the 
sulfates of steroid hormones are unable to bind to their cognate nuclear receptors 
(Hahnel, Twaddle et al. 1973).  
SULTs also catalyze the sulfation of a broad range of xenobiotics. Sulfation of 
xenobiotics is mainly associated with detoxification: biotransformation of a relatively 
hydrophobic xenobiotic into a more water-soluble sulfuric ester that is readily excreted. 
Nevertheless, it is noteworthy that a number of compounds can be converted into highly 
reactive intermediates by sulfation and can then act as chemical carcinogens and 
mutagens by covalently binding to DNA (Miller 1994; Glatt 1997).  Detoxification or 
bioactivation depend on the electrophilic reactivity of the individual sulfuric ester 
products formed. Most sulfation products are stable enough for excretion, while other 
sulfuric ester products can be reactive toward nucleophilic sites on DNA, RNA, and 
protein, and so become involved in the initiation of carcinogenesis and other toxic 
responses.  
 
1.1.2 Induciton of Cytochrome P450s 
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Phase I and phase II drug metabolizing enzymes are usually inducible by 
endogenous and xenobiotic compounds. Cytochrome P450s are the most well studied 
drug metabolizing enzymes. The induction of cytochrome P450 has long been a major 
driving force to attract many scientists into P450 research. Nuclear receptor mediated 
induction mechanisms of drug metabolizing enzymes are mostly revealed from the study 
of P450. Mammals contain at least 17 distinct P450 gene families. P450 gene families 1- 
4 (CYP1 – CYP4) code P450s that metabolize xenobiotics and endogenous lipophilic 
substrates. Other mammalian P450 gene families typically do not metabolize xenobiotics. 
Families 1 – 4 can be regulated by endogenous hormones, cytokines, and structurally 
diverse xenobiotics whereas other P450 gene families typically are not induced by 
xenobiotics (Waxman 1999). Induction of P450 gene expression is primarily through 
receptor-dependent mechanisms. 
CYP1 genes are stimulated through the aryl hydrocarbon receptor (AhR) 
(Hankinson, Brooks et al. 1991; Gonzalez, Liu et al. 1993). The AhR becomes activated 
by binding an aromatic hydrocarbon ligand in the cytosol. The activated receptor then 
translocates to the nucleus, heterodimerizes with the nuclear factor Arnt, binds to DNA 
enhancer sequences upstream of CYP1, and stimulates target gene transcription. This 
mechanism explains the induction of CYP1 genes by a large number of polycyclic 
aromatic hydrocarbons. 
CYP2B genes are regulated through the orphan nuclear receptor, constitutive 
active receptor (CAR) (Honkakoski, Zelko et al. 1998). This discovery advanced our 
understanding of the mechanism of phenobarbital (PB) induction. PB was the first 
cytochrome P450 inducer discovered (Sueyoshi and Negishi 2001). CAR binds to the PB 
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responsive element (PBRE) in CYP2B genes as a heterodimer with the RXR. The natural 
ligand for CAR is androstanes (Forman, Tzameli et al. 1998). Endogenous inhibitory 
steroids related to androstanol and androstenol bind to CAR and maintain it in an inactive 
state. In the presence of PB or PB-like inducers, the binding of inhibitory androstanes to 
CAR is abolished and receptor activity is thereby derepressed. CAR can directly 
transactivate a PBRE-linked reporter gene in transfected cells in the absence of PB 
inducers and inhibitory androstanes (Honkakoski, Zelko et al. 1998). 
CYP3 gene families can be induced by a broad range of steroids and antibiotics, 
including both glucocorticoids and anti-glucocorticoids. The orphan nuclear receptor, 
pregnane X receptor (PXR), was found to be responsible for most of these inductions 
(Cui, Thomas et al. 2005). PXR belongs to the nuclear hormone receptor family. Like 
non-steroid hormone receptors, PXR binds as a heterodimer with RXR to a hormone 
response element (HRE). PXR is activated by a large number of endogenous and 
exogenous compounds including steroids, antibiotics, antimycotics, bile acids, and 
components of the herbal antidepressant, St. John’s wort (Kliewer and Willson 2002). 
PXR serves as a generalized sensor of hydrophobic toxins. PXR is highly expressed in 
the liver and intestine (Kliewer, Moore et al. 1998; Kliewer and Willson 2002). This 
seems to be an indication that intestine, like liver, is an important organ for 
detoxification. PXR can also be activated by Phenobarbital (PB), suggesting that the 
effects of PB on CYP genes may be mediated by multiple receptors (Lehmann, McKee et 
al. 1998; Sueyoshi and Negishi 2001). 
CYP4A enzymes catalyze the oxidation of fatty acids. CYP4A genes can be 
transcriptionally activated by different acidic drugs and xenobiotics including 
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hypolipidemic fibrate drugs, phthalate ester plasticizers and other environmental 
pollutants (Rao and Reddy 2001). These inducers were first found to induce peroxisomal 
enzymes and are classified as peroxisome proliferator chemicals (PPCs) (Yeldandi, Rao 
et al. 2000). The receptor protein responsible for these inductions was named peroxisome 
proliferator-activated receptorα (PPAR)(Savas, Hsu et al. 2003; Nishimura, Yamauchi et 
al. 2005). PPARα mediated CYP4A6 induction is dependent on upstream enhancer 
elements in the CYP4A6 gene (Palmer, Hsu et al. 1994). Like CAR and PXR, PPARα 
binds as a heterodimer with RXR to the peroxisome proliferator response elements 
(PPREs). 
CYP7A enzymes catalyze hydroxylation of cholesterol. This reaction is the first 
and rate-limiting step for the catabolism of cholesterol to bile acids (Jelinek, Andersson et 
al. 1990). CYP7A gene is stimulated by cholesterol and suppressed by bile acids (Russell 
1992). Bile acids suppress CYP7A promoter activity through the farnesol X receptor 
(FXR). Bile acids, such as chenodeoxycholic acid (CDCA), lithocholic acid, and 
deoxycholic acid, are the natural ligands for FXR (Goodwin, Jones et al. 2000; Song, 
Echchgadda et al. 2001). FXR is also designated as BAR (bile acid receptor). The 
induction of CYP7A gene expression is mediated through liver X receptor-α  (LXRα). 
LXRα is activated through the binding of oxysterol (Lehmann, Kliewer et al. 1997). 
 
1.1.3 Induction of Sulfotransferases and Mechanism 
Induction of SULTs, though, hve not been well studied compared to other drug 
metabolizing enzymes, such as P450s, UDP-glucuronyltransferases (UGTs), and 
glutathione S-transferases (GSTs). SULT regulation and induction were not regarded 
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until the 1980s (Clarke, Adams et al. 1982).  Hormonal regulation and mRNA expression 
have been systematically studied by Dr.Curtis Klaassens’ research team using male and 
female rat livers (Liu and Klaassen 1996; Liu and Klaassen 1996; Liu and Klaassen 1996; 
Liu and Klaassen 1996; Liu, LeCluyse et al. 1996; Klaassen and Boles 1997; Boles and 
Klaassen 1998; Boles and Klaassen 1998; Dunn and Klaassen 1998; Klaassen, Liu et al. 
1998; Boles and Klaassen 1999; Dunn, Gleason et al. 1999; Dunn, Kolaja et al. 1999; 
Dunn and Klaassen 2000).  A total of six isoforms were examined.  They found that 
rSULT1A1 expression is not regulated by growth hormone; rSULT1C1 expression in 
male rats is controlled by male growth hormone secretory pattern; and rSULT1E2 
expression is suppressed by female growth hormone secretory pattern. The 
hydroxysteroid SULTs are primarily expressed in adult female rats. Synthetic 
glucocorticoid hormones, such as dexamethasone (DEX) and pregnenolone-16-alpha-
carbonitrile (PCN), are able to induce some rat hepatic SULT isoforms (Liu and Klaassen 
1996; Liu, LeCluyse et al. 1996). 
Studies on SULT regulation mechanism indicate some of the SULT isoforms 
through nuclear receptor mechanisms similar to cytochrome P450s (Runge-Morris, Rose 
et al. 1996; Runge-Morris 1998; Runge-Morris, Wu et al. 1999; Duanmu, Kocarek et al. 
2001; Wu, Kocarek et al. 2001; Duanmu, Locke et al. 2002). A cis-acting inverted repeat 
with three intervening bases (IR3) was identified in the 5’-flanking region of rat 
SULT1A1 which mediates transactivation by both the glucocorticoid receptor (GR) and 
the androgen receptor (AR) (Fang, Shenoy et al. 2003). The bile acid, chenodeoxycholic 
acid (CDCA), is a potent inducer of rSULT2A1, and its inducing effect is mediated 
through the bile acid-activated farnesoid X receptor (FXR) (Qian, Sun et al. 2001). The 
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ligand-activated FXR forms a heterodimer with the RXR and regulates rSULT2A1 by 
binding to an upstream region (an inverted repeat-0 nuclear receptor motif (IR0). An 
earlier report from the same research group demonstrated that androgens inhibit the 
rSULT2A1 promoter function (Chan, Song et al. 1998). PXR, which mediates CYP3A 
induction, mediated the induction of mSULT2A1 and PAPS synthetase 2 (PAPSS2) in 
mice (Sonoda, Xie et al. 2002). The results indicated that co-transfection of PXR, RXRα, 
and the IR0 element in the promoter region is necessary for the gene stimulation. This 
work demonstrated a binding site for PXR/RXR heterodimer within the mSULT2A1 
promoter (IR0), indicating that mSULT2A1 is the direct transcriptional target of PXR. It 
was proposed that PXR serves as a master regulator of phase I and II responses to 
facilitate rapid and efficient detoxification and elimination of xenobiotics. A study on the 
suppression of SULT2A1 during the acute phase response also suggested PXR and FXR 
are responsible for the induction of SULT2A1 (Ashikari-Hada, Habuchi et al. 2004).  
Recently, it was reported that the SULT2A1 in human, mouse and rat is a target 
for transcriptional activation by the vitamin D receptor (VDR) (Echchgadda, Song et al. 
2004). FXR and PXR inhibited vitamin D3 induction of SULT2A1. Another report also 
suggested a repressive role of PXR and FXR on basal mSULT2A1 expression (Kitada, 
Miyata et al. 2003). Using knockout mice and human cell lines, it was reported that 
multidrug resistance protein (MRP4), SULT2A1, CYP3A4, and CYP2B6 are induced by 
TCPOBOP and phenobarbital (PB) through CAR (CAR) (Assem, Schuetz et al. 2004). 
This suggests that MRP4 and SULT2A1 participate in an integrated pathway mediating 
elimination of sulfated steroid and bile acid metabolites from the liver. A study using 
transgenic mice demonstrated that CAR regulates mouse SULT2A9 expression by 
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binding to the CAR response elements found within the SULT promoters (Saini, Sonoda 
et al. 2004). It was concluded that this increased sulfation is responsible for bile acid 
detoxification (Falany and Wilborn 1994; Banoglu 2000; Zheng, Wang et al. 2003).  
The researches on the transcriptional regulation of hSULT2A1 have made 
impressive progress in recent years. Both steridogenic factor 1 (SF1) and estrogen-related 
receptor alpha (ERRα) were reported to regulate hSULT2A1 activity through the same 
DNA cis- element located in the proximal promoter region of hSULT2A1 (Saner, Suzuki 
et al. 2005; Seely, Amigh et al. 2005). Peroxisome proliferator-activated receptor alpha 
(PPARα) was also found to involve in the transcriptional regulation of hSULT2A1 
through the DNA response element located in - 5949 to -5929 upstream of the promoter 
region (Fang, Strom et al. 2005). The vitamin D receptor (VDR) was reported to target 
hSULT2A1 promoter through interaction with CAAT/Enhancer Binding Protein-alpha 
(C/EBPα) (Song, Echchgadda et al. 2005).  
Compared with endogenous growth and sex hormone, SULT induction by 
xenobiotics is not well studied. Recent data suggest that SULT can be induced by 
xenobiotics (Runge-Morris 1998; Runge-Morris, Rose et al. 1998; Maiti and Chen 2003a; 
Maiti and Chen 2003b; Gaworecki, Rice et al. 2004), although the mechanisms for 
induction are basically unknown. We previously reported that the antifolate and 
apoptosis-inducing drug, MTX, induces SULTs in rat liver/intestine (Maiti and Chen 
2003). In this study, MTX can induce hSULT in a time- and concentration-dependent 
manner. MTT assay results show the induction was not caused by the cytotoxicity. To 
investigate the mechanism involved in MTX induction of hSULT2A1, the promoter 
sequence was cloned. Cotransfection assay, and RNA intereference experiment found 
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CAR and RXRα were involved in the up-regulation of hSULT2A1. Promoter deletion, 
mutation and gel shift assay indicate that the IR2 element located in the promoter region 
of hSULT2A1 mediates the nuclear receptor induction of hSULT2A1.  Further studies 
have showed that PXR and VDR also regulate hSULT2A1 activity. There are cross-talk 
between different nuclear receptors and DNA-cis element. 
 
1.2 Methotrexate (MTX) 
Derivatives of the vitamin folic acid are crucial for the biosynthesis of 
thymidylate, purines and amino acids. They are necessary for normal metabolism and 
growth. Antifolates are the first antimetabolite class of anticancer agents and were one of 
the first modern anticancer drugs. The first clinically useful antifolate was 2,4-diamino-
pteroylglutamate (4-amino-folic acid; aminopterin; AMT) which was described in 1947 
(McGuire 2003). AMT was soon superseded by its 10-methyl congener, methotrexate 
(MTX). The structure of MTX is very similar to folic acid. MTX can inhibit the 
physiological functions of folic acid through tight-binding inhibition of dihydrofolate 
reductase (DHFR).  
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Detailed examination of the mechanisms of cytotoxicity and selectivity of MTX 
showed that inhibition of both dTMP synthesis and de novo purine synthesis, secondary 
to DHFR inhibition, led to DNA synthesis inhibition and subsequent cell death. For this 
reason, MTX is widely used as clinic drug against cancer and other diseases (Hine, 
Everson et al. 1990; Sakoda, Saitoh et al. 2003; Iikuni, Iwami et al. 2004).   
The transmembrane transport of MTX occurs by two different mechanisms in an 
energy dependent manner (Genestier, Paillot et al. 2000). The first route involves a 
transmembrane carrier protein; the affinity of this protein for MTX is very similar to 
reduced folates and is in the micromolar range. The second route involves a membrane 
associated folate binding protein. This transporter has a much lower affinity for MTX 
compared with reduced folates which is in the nanomolar range. The expression of both 
transporters increases when the concentration of extracellular folate is very low. At high 
concentration, MTX can passively diffuse into cells.  
MTX is converted to various forms of polyglutamate by linking up to five 
polyglutamate groups in vivo. This polyglutamation makes MTX readily transport across 
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the cell membrane. MTX and its polyglutamate metabolites inhibit activities of many 
enzymes in the metabolic pathway of folic acid. Long-term MTX therapy inhibits 
production of thymidylate, purine, and methionine and leads to accumulation of 
adenosine (Egan and Sandborn 1996). These actions inhibit cellular proliferation and 
induce apoptosis. In the treatment of cancer, the rationale for use of high dose MTX is 
that malignant cells become starved of the purine and pyrimidine precursors of DNA and 
RNA required for proliferation. The rationale for low-dose treatment of other diseases 
such as psoriasis, rheumatoid arthritis and inflammatory bowel disease is less clear 
(Fraser 2003). 
 Most study of MTX is clinically related. Reports on MTX induction of drug-
metabolizing enzymes are limited. Induction of cytochrome P450 (CYP) by MTX was 
not significant. Compared with other antineoplastic drugs, MTX possesses a lesser 
capacity for regulation of rat hepatic CYP enzymes. When the rat was administrated with 
MTX for 1, 2, 7, or 14 days, the mRNA level of CYP3A2 mRNA has almost no change 
and the mRNA level of CYP2C11 even marginally decreased (Cheung, Lee et al. 1996). 
Also the expression of CYP3A4 was not influenced by MTX in both reporter gene assays 
and endogenous induction studies (Luo, Cunningham et al. 2002). Microarray and real-
time RT-PCR analysis performed in drosophila indicated that many genes including those 
involved in signal transduction, transcription, and cell cycle regulation, were regulated by 
MTX (Affleck, Neumann et al. 2006). Here, we have investigated MTX induction 
mechanisms of hSULTs. 
 Through inhibiting several folate-dependent enzymes, the key enzyme for DNA 
and several amino acid synthesis, polyglutamated MTX can decrease the proliferation of 
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normal human bone marrow granulocyte progenitor cells and cause cytotoxicity 
(Koizumi, Ueno et al. 1990). The cytotoxicity of MTX to these cells can be completely 
reversed by equimolar concentration of 1-leucovorin. MTX was also reported to inhibit 
proliferation of human epidermal keratinocytes and induce differentiation of the cells in 
vitro. The inhibition effect of MTX is time- and dose- dependent and becomes 
irreversible after 24 hours. Thymidine can completely prevent these effects caused by 
MTX, suggesting all these effects are caused by a depletion of thymine 
deoxyribonucleotides (Omata, Abraham et al. 1992). MTX also induces the 
differentiation of monocytic tumor cells, which may explain, in part, its therapeutic 
effects in the treatment of some disorders (Zimecki and Artym 2004).  
 
1.3 Nuclear Receptors 
1.3.1 General 
Nuclear receptors (NRs) are a large family of transcriptional factors that bind to 
specific regulatory sequences in DNA, and regulate the transcription of many proteins. 
Ligands of nuclear receptors are normally small and lipophilic, properties that similar to 
those of endogenous inducer compounds such as steroids, bile acids, or fatty acids. The 
activities of nuclear receptors are regulated by their ligands, phosphorylation, and by 
interaction with other proteins (Astapova, Smirnov et al. 2002). Nuclear receptors play an 
important role in normal physiological development and metabolism and represent 
therapeutic targets for a wide range of human diseases including cancer, endocrine and 
heart disease (Nettles and Greene 2005). A typical nuclear receptor contains a variable 
NH2-terminal region, a conserved DNA-binding domain (DBD), and a conserved 
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carboxy-terminal  ligand binding domain (Aranda and Pascual 2001). Some nuclear 
receptors also contain an amino-terminal activation function (AF1), which can activate 
transcription in a ligand-independent fashion. The nuclear receptor ligand binding 
domain (LBD) contains a second activation domain, termed AF-2, which is located in the 
COOH terminus of the LBD, unlike the AF-1 domain, the AF-2 domain is strictly ligand 
dependent and conserved among the members of the nuclear receptor superfamily. 
Coactivators bind to the AF2 surface via the amino acid motif LxxLL. The mechanism of 
transcriptional activation by NRs is via recruitment of these coactivators, which mediate 
chromatin remodeling and also recruit the basal transcription apparatus (Nettles and 
Greene 2005). 
Evolutionary analysis of the nuclear receptors has led to a subdivision in six 
different subfamilies (Laudet 1997). The first subfamily includes CAR (CAR/MB67), 
pregnane X receptor (PXR), Farnesoid X receptor (FXR), liver X receptor (LXR), thyroid 
hormone receptors (TRs), retinoic acid receptors (RARs), vitamin D receptors (VDRs) 
and peroxisome proliferators-activated receptors (PPARs). The second subfamily 
includes retinoid X receptors (RXRs) together with HNF4 orphan nuclear receptors. 
Almost all nuclear receptors in the first subfamily form heterodimer with RXRα and 
regulate transcription of their target genes. RXRα is a common hetorodimer partner of 
nuclear receptor. The third subfamily contains steroid receptors and the estrogen-related 
receptors (ERRs). The fourth, fifth, and sixth subfamilies contain the nerve growth factor 
increased protein B (NGFI-B), Fushi Tarazu-factor 1 (FTZ-1), and germ cells nuclear 
factor (GCNF), respectively. 
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Although most nuclear receptors transactivate their targets after binding to their 
recognition sequence, nuclear receptors can also inhibit gene expression. In some cases, 
inhibition may come from nuclear receptors competition for DNA binding sequences 
with other nuclear receptors or transcription factors. However, there are also so-called 
negative DNA response elements (Drouin, Trifiro et al. 1989). The negative DNA 
response element represses the expression of the target gene by binding with specific 
transcription factors. Negative DNA response element is usually located very close to the 
transcriptional start site (Saatcioglu, Perry et al. 1990). 
 
1.3.2 Cross-talk between Nuclear Receptors 
Nuclear receptors are part of a complex network of transcription work in vivo. It 
is not surprising that different nuclear receptors can interact with a variety of other 
proteins as well as one another in different signaling pathways (Pascussi, Gerbal-Chaloin 
et al. 2003). Between CAR and PXR, a considerable redundancy exists with regard to 
overlapping ligands and the binding of both receptors to the DNA-response elements with 
overlapping affinity (Moore, Parks et al. 2000; Maglich, Stoltz et al. 2002; Zhang, Huang 
et al. 2004). PXR and CAR might thus compensate for the loss or malfunction of one 
another to a certain degree, which might explain the lack of an obvious phenotype in the 
PXR or CAR knockout animals (Zhang, Huang et al. 2004). In the case of heterodimeric 
receptors, competition for limiting concentrations of RXR presents a mechanism of 
transcriptional regulation for several nuclear receptors.  
Nuclear receptors can also regulate gene expression by mechanisms independent 
of binding to DNA response element. This means they can alter the expression of genes 
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that do not contain any DNA response element through positive or negative interfere with 
the activity of other transcription factors. This mechanism is generally referred to as 
transcriptional cross-talk (Gottlicher, Heck et al. 1998). It was reportered that several 
nuclear receptors, such as retinoic acid receptor, glucocorticoid receptor, etc. can act as 
ligand-dependent transrepressors of AP1 activity. AP1 can also inhibit transactivation by 
nuclear receptors (Pfahl 1993). The cross-talk between nuclear receptors and other 
signaling pathways is not restricted to the transcriptional antagonism described above. 
Phosphorylation of nuclear receptors provides an important link between signaling 
pathways (Shao and Lazar 1999). Also, nuclear receptors can affect the rate of RNA 
polymerase II-directed transcription. This interaction may occur directly or indirectly 
through the action of coactivators or corepressors. Nuclear receptors to interact with 
several components of the general transcriptional machinery (Schulman, Chakravarti et 
al. 1995). It is likely that the nuclear receptors can cause the recruitment of basal 
components of the promoter and the enhancement of transcription. 
 
1.3.3 CAR, PXR and VDR         
Several mechanisms of how CAR (Constitutive Androstane/Active Receptor) 
regulate drug mechanism have been proposed so far.However, none of them explain the 
whole process of signal transduction (Kawamoto, Sueyoshi et al. 1999). CAR normally 
resides in the cytoplasm of hepatocytes and undergoes a cytosolic-nuclear translocation 
upon phenobarbital treatment (Kawamoto, Sueyoshi et al. 1999). As a result, CAR can 
induce the gene expression of CYP2B6. The androstanol can reverse the effect of CAR. 
However, it is unknown whether this reversal of inhibition is due to a direct interaction 
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with CAR. In addition to derepression, direct activation of CAR by a few chemicals has 
been reported. The chemical TCPOBOP is one of the strongest inducers in mouse but 
hardly affects CYP2B levels in human (Tzameli, Pissios et al. 2000). Interestingly, 
CITCO has strong effect on human CYP2B6 but has little effects on mouse CYP2B 
(Maglich, Parks et al. 2003). Differences in activation of CAR in mouse and human are 
most likely due to the divergent ligand binding domain of the CAR orthologs from these 
species (Moore, Parks et al. 2000). Furthermore, CAR activity in the nucleus seems to  be 
under the regulation of protein phosphorylation events (Zelko, Sueyoshi et al. 2001). 
In contrast to the classical nuclear receptors, CAR shows both ligand dependent 
and ligand independent activities. Phenobarbital activates both human and mouse CAR 
through translocating CAR from the cytoplasm to the nucleus (Honkakoski and Negishi 
1998). Because CAR exhibits an intrinsically high transcriptional activity, nuclear 
localization of the receptor results in the activation of target gene expression in the 
absence of ligand binding (Forman, Tzameli et al. 1998; Honkakoski and Negishi 1998). 
The nuclear receptor pregnane X-receptor (PXR) can bind to a wide variety of 
structurally diverse exogenous and endogenous chemicals and regulate the expression of 
genes important to drug disposition process such as drug transporters, phase I and II 
metabolic enzymes (Watkins, Wisely et al. 2001; Carnahan and Redinbo 2005). Nuclear 
vitamin D receptor (VDR) is known to mediate the biological actions of 1α,25-
dihydroxyvitamin D3 through its ability to modulate the expression of target genes 
(Nezbedova and Brtko 2004). All the three nuclear receptors CAR, PXR and VDR share 
a common heterodimerization partner, retinoid X-receptor (RXR), and are subject to 
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cross-talk with other nuclear receptors and with a broad range of other intracellular 
signaling pathways. 
 Our laboratory has found that MTX can induce hSULT2A1 by both endogenous 
induction (Chen, Baker et al. 2005) studies and reporter gene assay. The molecular 
mechanism involved this induction remains to be elucidated. The present project 
investigated the nuclear receptors involved in MTX induction of hSULT2A1. We found 
that several nuclear receptors including CAR, PXR, and VDR can regulate the expression 
of hSULT2A1. CAR has synergistic effect with MTX; CAR and MTX together can 
significantly up-regulate the promoter activity of hSULT2A1. PXR represses the 
promoter activity of hSULT2A1 and can reverse the induction effect of MTX and CAR 
on hSULT2A1. VDR can also transactivate hSULT2A1 and compete with CAR for the 
promoter activity of hSULT2A1. 
 
1.3.4 Coactivators and Corepressors 
Different cloning strategies have led to the identification of numerous receptor-
coactivator proteins which include estrogen receptor associated proteins (ERAPS) 
(Halachmi, Marden et al. 1994), receptor-interacting proteins (RIP) (Cavailles, Dauvois 
et al. 1994), or thyroid receptor-associated proteins (TRAPs) (Fondell, Ge et al. 1996). 
These coactivator proteins interact with nuclear receptors in a ligand dependent manner. 
A possible application derived from the ligand-dependent recruitment of coactivators by 
the nuclear receptors is the identification of new ligands. An assay termed coactivator-
dependent receptor ligand assay (CARLA) using SRC-1 has allowed for the identification 
of naturally occurring ligands for different nuclear receptors (Krey, Braissant et al. 1997; 
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Walfish, Yoganathan et al. 1997; Devchand, Hihi et al. 1999). Although most 
coactivators interact with the nuclear receptors in a ligand-dependent manner and require 
the AF-2 domain, some coregulators, including p68 and PGC-1 interact with the AF-1 
domain. Other coactivators could be involved in protein degradation, RNA stability, or 
nuclear transport (Aranda and Pascual 2001). 
In addition to the ligand-dependent gene activation, nuclear receptors including 
TR and RAR repress basal transcription in the absence of ligand. Binding of hormonal 
ligand to the receptor releases the transcriptional silencing and leads to gene activation. 
Biochemical studies of cellular proteins associated with free thyroid receptor and RAR 
led to the identification of a 270-kDa cellular protein named nuclear corepressor (NCoR) 
(Horlein, Naar et al. 1995), or RIP-13 (Seol, Mahon et al. 1996). In parallel, silencing 
mediator for retinoic and thyroid hormone receptors (SMRT) was isolated by a yeast two-
hybrid screening of a human lymphocyte cDNA library (Chen and Evans 1995).  Free TR 
and RAR interact strongly in vitro with NCoR and SMRT, and addition of ligand induces 
dissociation from the corepressors. It appears that the AF-2 region serves to trigger the 
release of corepressors from the nuclear receptors upon the binding of ligand. 
 
1.4 Hormone Response Elements 
Nuclear receptors regulate transcription by binding to specific DNA sequences in 
target genes known as hormone response elements (HREs). These elements are usually 
located in the proximal promoter region of the target genes. In rare cases, they can 
present in the enhancer region which is located several thousand base pairs upstream of 
the transcriptional start site (Fang, Strom et al. 2005). The analysis of both naturally 
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occurring as well as synthetic HREs revealed that a sequence of 6 bp constitutes the core 
recognition motif. Two consensus motifs have been identified. The sequence AGAACA 
is recognized by steroid class III receptors, and AGGTCA serves as recognition motif for 
all other receptors (Beato, Herrlich et al. 1995). The two half-site motifs can be separated 
by various numbers of base pairs. Most nuclear receptors bind to their HREs as homo- or 
heterodimers composed typically of two core hexameric motifs. The two half-sites of the 
HREs can be configured as directed repeats (DR), inverted repeats (IR), or everted 
repeats (ER). In some cases, nuclear receptor can bind to HREs as monomers (Seely, 
Amigh et al. 2005). 
Except for the core recognition motif, the small differences in the half-site 
sequence and the sequence of the flanking extension of the response elements also play 
important role in determining receptor binding specificity (Mader, Leroy et al. 1993) 
 
1.5 RNA Interference 
RNA interference (RNAi) is the suppression of gene expression at the 
transcription level by nucleotide sequence-specific interactions that are mediated by 
RNA. In a natural context, dsRNA may be produced from rearranged loci, by 
transcription from converting promoters or by host or viral-encoded RNA-dependent 
RNA polymerases (Voinnet 2002). A key component of RNA silencing is a 21-23 
nucleotide RNA known as small interfering RNA (siRNA). In Drosophila, the siRNA is 
derived from dsRNA by the action of an RNaseIII-like enzyme named DICER 
(Bernstein, Caudy et al. 2001). The siRNA guides the formation of a multi-subunit 
endonuclease, referred to as the RNA-induced silencing complex (RISC), and RISC 
 19
directs the degradation of target mRNA. The regulation of siRNA is very specific and the 
regulated mRNA often shares sequence similarity with the inducing dsRNA (Hammond, 
Bernstein et al. 2000; Zamore, Tuschl et al. 2000). 
For in vitro study, RNA intereference can be induced in mammalian cells by the 
introduction of synthetic double-stranded small interfering RNA, which is 21-23 base 
pairs (bp) in length or by plasmid and viral vector systems that express double-stranded 
short hairpin RNAs that are subsequently processed to small intereference RNA by the 
cellular machinery.  
Besides its extensive application in basic research, RNAi technology was also 
used to analyze quickly the function of a number of genes in a variety of organisms. For 
instance, in D. melanogaster, RNAi technology has been successfully used to identify 
genes with essential roles in signaling transduction cascades, embryonic development, 
and other basic cellular process (Li, Clemens et al. 2000).  Given the gene-specific 
features of RNAi, this technology will play an important role in disease therapeutic 
applications. Since siRNA targets cellular mRNA, they are potential therapeutic reagents 
because of their power to down-regulate the expression pattern of mutant genes in 
diseased cells.  Recently, the therapeutic potential of the siRNA technique has been 
demonstrated in vivo in mouse models. The hepatitis C virus and the fas gene can be 
effectively knocked down by RNA interference in mouse liver (McCaffrey, Meuse et al. 
2002; Song, Lee et al. 2003). Undoubtedly, the RNA interference technology will 
become a useful tool in drug metabolism enzyme study. In recent years, RNA 
interference was widely used in nuclear receptor transcriptional regulation studies 
(Marquez, Chen et al. 2005; Rigamonti, Helin et al. 2005; Sola, Amaral et al. 2005). In 
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our experiment we transfected chemically sythesised CAR specific siRNA, we found that 
after the CAR activity was knocked down by siRNA, the expression of hSULT2A1 in 
Caco-2 cells signicantly decreased. This indicates that CAR is involved in the 
transcriptional regulation of hSULT2A1. Our results indicate that siRNA is a useful tool 
in investigating the transcriptional regulation of human sulfotransferase. 
 
1.6 Significance of the Research 
SULTs are important in the regulation of biological signaling molecules. They 
also play important roles in xenobiotic detoxification and carcinogen bioactivation. 
Knowledge of hSULTs induction mechanisms could have a significant impact on cancer 
prevention, toxicology, drug design and development, drug-drug interaction, food safety, 
and general human health. Induction of hSULTs during cancer treatment can lead to drug 
resistance as well as increase the bioactivation of procarcinogens and promutagens. An 
understanding of xenobiotic induction of hSULTs may provide clinicians with a measure 
to evaluate a patient’s ability to tolerate drugs that are metabolized by SULTs. The 
research results will lead to a better understanding in SULTs' biological functions and 
their potential roles in cancer prevention and causation.  
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Chapter II 
Hypothesis and Objectives 
2.1 Hypothesis  
 Drug metabolizing enzymes can be induced by endogenous and xenobiotic 
compounds. The induction mechanism involves different nuclear receptors interacing 
with DNA cis-elements located in the proximal promoter region of the drug metabolizing 
enzymes. In this project, we want to test if the widely used anti-folate drug MTX can 
induce the expression of hSULTs. Through endougenous induction study, we found 
MTX can induce the four major families of hSULTs in both Caco-2 and Hep G2 cells, 
and then we start to investigate the MTX induction mechanism. Because hSULTs belong 
to phase II drug metabolizing enzymes, we hypothesize the MTX induction mechanim of 
hSULTs is similar to the induction mechanism of other drug metabolizing enzymes. We 
propose some nuclear receptors are involved in the transcriptional regulation of hSULTs. 
Among these nuclear receptors, RXRα function as a common heterodimer parterner, it 
interacts with other nuclear receptors and mediates the transcriptional regulation of 
hSULTs. We hypothesize that some DNA cis-elements located in the proximal promoter 
region of hSULTs also play very important function in hSULT regulation. These DNA 
cis-elements interact with nuclear receptors and regulate the gene expression of hSULTs. 
So the overall goal of our research is to find out the nuclear receptors and DNA cis-
elements involved in the transcriptional regulation of hSULTs.
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The following diagram describes the system we are investigating. hSULTs are the 
target gene in our study. We want to investigate the transcriptional regulation of these 
genes. We use human cell line Hep G2 and Caco-2 cells as models, we first directly 
treated Hep G2 and Caco-2 cells with MTX, we found MTX can  induce the expression 
of hSULTs in both Hep G2 and Caco-2 cells, and then we start to investigate the MTX 
induction mechsniam of hSULTs. We hyphthesize the regulation of hSULTs are 
mediated through the interation of nuclear receptors with DNA-cis element located in the 
proximal promoter region of hSULTs. So the major task of this study is to find out the 





































Figure 2.1.1 System may involved in MTX induction of hSULTs. 
The model system in this diagram is the human Hep G2 cells and human Caco-2 cells. 
The ourter circle in the figure represents the cell membrane; the inner circle in the figure 
represents the nuclear membrane. The target gene in this system is the hSULT. When the 
cells were treated with MTX, the expression of hSULT, including both the mRNA 
expression and protein expression, was up-regulated by MTX. We hyphothesized the 
MTX induction is mediated through the interaction of nuclear receptors with the DNA 
cis-element located in the proximal promoter region of hSULT gene. 
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2.2 Experimental Objectives 
  In our studies, we use human Hep G2 and human Caco-2 cell lines as model to 
investigate the hSULT induction mechanism because human cell lines are easy to 
manipulate and the experiment is easy to repeat. Hep G2 cells are derived from human 
liver and Caco-2 cells are derived from human colon. It was believed that human liver 
and human intestine are the two major organs that involved in drug metabolism. The 
aboundance of hSULTs in both Hep G2 and Caco-2 cells are very high, it is easy to 
detect the expression of hSULTs through RT-PCR and western blot methods. To 
investigate the effect of MTX to hSULTs, we directly treated Hep G2 and Caco-2 cells 
with different concentrations of MTX for different time, and then we harvested the MTX 
treated cells and detected the mRNA and protein level of hSULTs through RT-PCR and 
western blot. With hSULTs catalyzed substrate specific sulfation reaction, we can also 
detect the enzymatic activities of hSULTs. Interestingly, MTX can significantly induce 
most tested hSULTs in both Hep G2 and Caco-2 cells. Then we start to investigate the 
MTX induction mechanism of hSULTs. 
To investigate the MTX induction mechanism of hSULTs, we cloned the 
promoter sequences of hSULTs through PCR with human genomic DNA extracted from 
Hep G2 cells. The cloned promoter sequences were ligated to the pGL3-Basic luciferase 
reporter vector so that the expression of the luciferase was regulated by the promoter 
sequences of hSULTs. The constructed reporter vectors were used in reporter gene assay 
and the cloned promter sequence was tested for their promoter activities. The biological 
functional reporter vectors were used in dual luciferase assay for MTX time- and 
concentration-dependent induction study. So the MTX induction of hSULTs was 
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confirmed by both endogenous study and reporter gene assay. Further experiments were 
designed to figure out the MTX induction mechanism of hSULTs. 
It is well know that high concentration of MTX can cause cytotoxicity to human 
cells. To test if the MTX induction of hSULTs was caused by MTX cytotoxicity, we did 
MTT assay to test the MTX cytotoxicity to Hep G2 and Caco-2 cells.The concentrations 
of MTX used in MTT assay are the same as dual luciferase assay. Through comparing the 
MTX cytotoxicity pattern with the MTX induction pattern, we know the MTX induction 
of hSULTs was not caused by it cytotoxicity. So there must be other induction 
mechanisms involved in MTX induction of hSULTs, we hypothesize the induction was 
mediated through the interaction of nuclear receptors with DNA cis-elements located in 
the proximal promoter region of hSULTs. 
To find the nuclear receptors involved in the transcriptional regulation of 
hSULTs, we cotransfected different nuclear receptors together with the reporter vector 
which contain the 5’ flanking region of hSULT promoters. If some nuclear receptors are 
involved in the regulation of hSULTs, the cotransfection of these nuclear receptors will 
be able to change the activity of the reporter gene which is regulated by the promoter 
sequence of hSULT. After we find some nuclear receptors can regulate the promoter 
activities of hSULTs, we can design other independent experiments to further prove the 
role of these nuclear receptors involved in hSULT regulation. For example, we can 
transfect siRNA specific to these nuclear receptors and then detect the expression of 
hSULTs. Most nuclear receptors are ligand dependent, so we can also use specific ligand 
of nuclear receptors to test the function of nuclear receptors. 
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The promoter sequences we cloned is at least more than 800bp upstream of the 
transcription start site of hSULTs, while the DNA cis-element that can interact with 
nuclear receptors are less than 20bp, so we need to narrow down the promoter sequences 
to a small range. For this purpose, we can use the step wise promoter deletion to make the 
promoter sequences become short. After we locate the DNA cis-element to a relative 
small range of promoter sequence, we can do DNA sequence alignment, by comparing 
our promoter sequences with other characterized DNA cis-element, we can find some 
candidates. With the DNA mutation experiment, we can test the function of the selected 
DNA cis-element. If some DNA cis-element is very important in the MTX induction of 
hSULT, the mutation of this sequence will be able to abolish the MTX and nuclear 
receptors mediated hSULT induction. 
After we find both the nuclear receptors and the DNA cis-elements involved in 
hSULT regulation, we can use the electrophoretic mobility shift assay (EMSA) to test the 
interaction between nuclear receptors and DNA cis-elements. The nuclear extract from 
Caco-2 and Hep G2 cells can be used as protein sourse in the EMSA assay. Throug the 
EMSA assay, the specificity of the DNA cis-element can be confirmed. To verify the 
specificity of the nuclear receptors, super shift assay can be carried out and find out the 
specific nuclear receptors that interact with the DNA cis-elements. 
It was reported that nuclear receptors can interact with each other and cross-talk 
with different transcription factors and DNA cis-elements. If we find several nuclear 
receptors can regulate the expression of hSULTs, we want to see if there is cross-talk 
between these nuclear receptors. To test the cross-talk between different nuclear 
receptors, we can cotransfect different nuclear receptors together with reporter vectors 
 27
into Hep G2 or Caco-2 cells. If several nuclear receptors can all bind to the verified DNA 
cis-elements, the cotransfections of these nuclear receptors will interefere with each 
other. These transfected nuclear receptors can compete with the same DNA cis-element; 





Materials and Methods 
 
3.1 Materials  
 MTX was obtained from ICN Pharmaceuticals (Aurora, Ohio). [1,2,6,7- H(N)] 3
Dehydroepiandrosterone ([ H] DHEA, 60 Ci/mmol) and [2,4,6,7- H(N)]estradiol ([ H]E , 
72 Ci/mmol) were purchased from NEN (Boston, MA). β-naphthol, [ C]2-naphthol (4.7 





diphenyltetrazolium bromide (MTT), 9-cis-Retinoic acid, and 3'-phosphoadenosine-5’-
phosphosulfate (PAPS) were purchased from Sigma-Aldrich (St. Louis, MO). SDS-
polyacrylamide gel electrophoresis reagents were obtained from Bio-Rad (Hercules, CA). 
Western blot chemiluminescence reagent kits (Super Signal West Pico Stable Peroxide 
and Super Signal West Pico Luminol/Enhancer solutions) were purchased from Pierce 
Chemical (Rockford, IL). Nitrocellulose membrane (Immobilon-P; Millipore 
Corporation, Bedford, MA) used in Western blot procedure was purchased from Fisher 
Scientific Co. (Fair Lawn, NJ). Antibodies against hSULT1A3, SULT2A1 and 1E1 were 
supplied by Panvera. Antibody against hSULT1A1 was a gift from Dr. Charles N. 
Falany’s laboratory of the University of Alabama at Birmingham. All other reagents and 
chemicals were of the highest analytical grade available.
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DNA restriction enzymes, Wizard® SV Genomic DNA Purification System and 
Access RT-PCR System were purchased from Promega (Madison, WI). One Shot® Top 
10 competent cells and Lipofectamine™ 2000 were from Invitrogen (Carlsbad, CA). 
Cells culture medium and 0.25% trpsin-EDTA was from Sigma. The characterized FBS 
and charcoal stripped FBS were purchased from Hyclone. The plasmid extraction kit and 
total RNA extraction kit were from QIAGEN (Valencia, CA). The DNA gel purification 
kit was from Q-Biogene (Carlsbad, CA). Protein assay reagent was from Bio-Rad 
(Hercules, CA). The DIG Gel Shift Kit, 2nd Generation (Cat. No. 03353591910) was from 
Roche Applied Science. Retinoid X receptor (RXRα) plasmid was from Dr. Ronald M. 
Evans’s laboratory (Howard Hughes Medical Institute, La Jolla, CA). CAR plasmid was 
from Dr. Steven A Kliewer’s laboratory (University of Texas Southwestern Medical 
Center, Dallas, TX). 
 
3.2 Cell Culture and Drug Treatment 
  Both Hep G2 and Caco-2 cells were obtained from American Type 
Culture Collection (Manassas, VA). Hep G2 Cells were grown and maintained in 
Dulbecco’s modified eagles’s medium nutrient mixture F-12 ham (Sigma) supplemented 
with 10% fetal bovine serum (FBS). Caco-2 cells were grown and maintained in 
Dulbecco’s modified eagles’s medium (Sigma) supplemented with 20% fetal bovine 
serum (FBS).  The cultures were incubated at 37°C in a humidified incubator containing 
5% CO2, 95% air. MTX dissolved in 10 mM sodium hydroxide was added to the cells 
with a final concentration as required and incubated for different time as indicated. The 
vehicle control group received only 10 mM NaOH so as the final concentration of NaOH 
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is 0.2 mM. Folic acid was dissolved in the culture medium directly. Retinoic acid and 
vitamin D3 was dissolved in ethanol. CITCO was dissolved in dimethyl sulfoxide 
(DMSO). To avoid the ethanol and DMSO cause significant effect to human 
sulfotransferase, all vehicle concentration added to cells was kept at 0.1% (V/V) with 
final concentration. Cells were collected after induction.  Total RNA was extracted for 
RT-PCR and cytosol was prepared for enzymatic assay and Western blot. 
 
3.3 Cytosol Preparation 
Both Hep G2 and Caco-2 cells were detached from their culture dishes using 
0.25% trypsin- EDTA solution (Sigma) and washed with phosphate buffered saline.  The 
cells pallet was dissolved and homogenized in 300 μl buffer [NaCl: 150 mM, Tris: 20 
mM, EDTA: 1 mM, DTT: 1 mM, Trypsin Inhibitor: 0.1 mg/ml, Tween-20: 0.3% (V/V), 
PMSF: 1 mM].  The debris was removed by centrifugation at 13,000 RPM for 10 min and 
the supernatant was used in the following enzymatic assay and western blot. 
 
3. 4 Enzyme Assays 
3.4.1 PNPS Assay  
2-Naphthol sulfation activity from Hep G2 cells was determined as previously 
described (Chen, Battaglia et al. 1999; Chen, Zhang et al. 2003). This assay determines 
the activities of different isoforms of phenol sulfating SULTs. Briefly, sulfation activity 
was determined in a reaction mixture containing 50 mM Tris buffer, pH 6.2, 5 mM 
PNPS, 20 μM PAPS, and 0.1 mM 2-naphthol. Hep G2 cell cytosols (50 μg protein) were 
used as the enzyme source in a total reaction volume of 250 μl. After 30 min incubation 
 31
at 37 ° in a shaking water bath, the reaction was stopped by adding 250 μl of 0.25 M Tris, 
pH 8.7. The reaction mixtures were read at 401 nm in a spectrophotometer. Specific 
activity was expressed as nanomoles per minute per milligram of protein. The data shown 
in the figures are the average of three independent experiments. 
 
3.4.2 Radioactive Assay 
enzymatic activities of hSULT2A1, hSULT1E1, hSULT1A1 in the cytosol was 
determined using the radioactive assay method as previously described (Chen, Zhang et 
al. 2003; Maiti and Chen 2003; Maiti and Chen 2003). Two hundred micro-grams for 
Caco-2 cytosol, 50 μg for Hep G2 cytosol were used for each assay. Other ingredients 
and reaction conditions were the same as the PNPS assay mentioned above. Radioactive 
[3H] estradiol (0.15 μM, 0.4 Ci/mmol for store concentration) and [3H] DHEA (2 μM, 1.0 
mCi/mmol for store concentration) were used as specific substrate for SULT1E1 and 
SULT2A1 assay, respectively. [14C] 2-naphthol (0.1 mM, 4.7 mCi/mmol) was used for 
hSULT1A1 activity in Caco-2 cells. For all assays, 20 μM PAPS was used. All 
enzymatic reactions were performed in a total reaction volume of 250 μl. After 30 min 
incubation at 37 ° in a shaking water bath, the reaction was stopped by adding 250 μl of 
0.25 M Tris, pH 8.7. Extraction was performed twice by addition of 0.5 ml of water-
saturated chloroform. After the final extraction, 100 μl of aqueous phase was used for 
scintillation counting. Data from radioactive assay represent the average of three 
independent experiments. PAPS was eliminated from the controls of all assay methods. 
Assays were run in duplicate and the average of the results was used for enzyme activity 
calculations. 
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3.5 Western Blot Analysis   
Cytosol protein from Hep G2 cells (10 μg) and Caco-2 cells (15 μg) was used in a 
12% polyacrylamide gel in an electrophoresis system (Novex, San Diego, CA, USA). 
After running at 120 V, the protein bands were transferred overnight at 150 mA onto a 
PVDF membrane. All membranes were blocked in TBST (50 mM Tris, pH 7.5, 150 mM 
NaCl, 0.05% (v/v) Tween-20) containing 5% (w/v) dry milk for 1 hr on a shaker at room 
temperature. The membranes with proteins from Hep G2 and Caco-2 cells were 
incubated separately with anti-hSULT1A1, anti-hSULT1A3, anti-hSULT2A1, and anti-
hSULT1E1 (1:2000) in TBST containing 5% (w/v) dry milk overnight at 4 °C. After 
incubation, all membranes were washed with TBST for 4×15 min and incubated in 
secondary antibody (horseradish peroxidase-conjugated Immuno-Pure goat anti-rabbit 
IgG; H+L) at 1:5000 dilutions in the same buffer for 2 hours. The membranes were 
washed with TBST for 4×15 min. Fluorescent bands were developed with 4 ml of 
substrate containing same volume of each Super Signal West Pico Luminol Enhancer 
solution and Super Signal West Pico stable Peroxidase solution at room temperature for 5 
min. The X-ray films were exposed to the membrane and then developed. Films were 
scanned and the densitometric analysis was performed in a Gel Documentation and 
Analysis System from Advanced American Biotechnology (AAB) and with AAB 
software (Fullerton, CA, USA). 
 
3.6 Extraction of Total RNA and RT-PCR 
 RNeasy Mini protection kit from Qiagen was used for total RNA extraction.  One 
Step RT-PCR kit from Promega was used for RT-PCR.  The primer pairs were designed 
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using the software primer 3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).  
The primers were synthesized by IDT. Specific primers for different human SULTs are as 
follows: hSULT1A1, forward: 5'- GAT TCC CTC AGG GAT GGA -3', reverse: 5'- GTG 
TGC TGA ACC ACG AA -3'. hSULT1A3, forward: 5' -TGA GCC AGA TAC TGG 
ACA -3', reverse: 5'- CCG TAG GAC ACT TCT CCA -3'.  hSULT2A1, forward: 5'- 
CCC CAA ATC AGG AAC AAA C -3', reverse: 5'- CCA GAA AAA ATA ACC AGA 
CAC C -3'.  Human beta actin (for control), forward: 5'- GGC GGC AAC ACC ATG 
TAC CCT -3', reverse: 5'- AGG GGA GGG ACT CGT CAT ACT -3'.  The specificity of 
all primers was tested using the BLAST of the National Center for Biotechnology 
Information Open Reading Frame software. cDNA synthesis from total 0.1 μg of Hep G2 
cells total RNA and 0.2 μg of Caco-2 cells total RNA was performed in a 25 μL reaction 
mixture. The concentrations of the different ingredients in the PCR reaction were used 
following supplier’s protocol. For the control, 200-bp cDNA of human β -actin was 
synthesized from the same amount of RNA from respective cells.  
 
3.7 MTT Assay 
Cell viability was tested using MTT (3-(4 to 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay (Sigma-Aldrich) based on the capability of the 
mitochondrial succinate-tetrazolium reductase system to convert the yellow dye (MTT) to 
a blue formazan (Mosmann 1983). Following treatment with MTX, the cell culture 
medium was replaced with serum free medium and the cells were treated with MTT stock 
solution (5 mg/ml, 10 ul) and incubated at 37oC. After 4 hours, 100 µL of dimethyl 
sulfoxide (Sigma-Aldrich) was added to lyse the cells and solubilize the formazan 
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reaction product. Thirty minutes later, the 96 well plates were read in a microplate reader 
(Wallace 1420 Victor 2, Perkin Elmer Inc, Boston, MA, USA) at 550 nm. 
 
3.8 Construction and Mutagenesis of hSULT2A1 Promoter Reporter in Caco-2 Cells 
Luciferase reporter constructs were used in the transfection studies.  Primer 
designed for the hSULT2A1 promoter sequence was based on previously described 
(Otterness, Her et al. 1995; Duanmu, Locke et al. 2002).  Briefly, a fragment containing 
the 5’-flanking region (-1463 to +48) of hSULT2A1 was generated by PCR using 
genomic DNA extracted from Hep G2 cells.  The fragment was inserted into the 
luciferase reporter vector pGL3-Basic (Promega, Madison, WI) at the MluI and XhoI sites 
to drive the promoterless firefly luciferase gene.   
Reporter plasmids containing nested deletions of the SULT2A1 5’- flanking 
region were all generated by PCR reactions. Specifically, constructs –713, -414, -354, -
235, -188, -130 and –65 were generated by using a –1463 to +48 fragment of the 
hSULT2A1 gene as template. A series of 5’ primers were designed to incorporate a SacI 
site for sub-cloning (5’- TTACATACACGTCAGCCATCAA - 3’ for construct-713, 5’ – 
TGTGGTCTTTTGGATTTGGAG - 3’ for construct-414, 5’-
GCACGATTGCAGGATTATTT - 3’ for construct –354, 5’- 
TTGTCCTCGTGTTTGTTATTCG - 3’ for construct –235, 5’- 
CAAGCTCAGATGACCCCTAAA - 3’ for construct –188, 5’- 
CAATCTTTTGAGTATGG GTCACA - 3’ for construct –130, and 5’- 
GTGACATGCTGGGACAAGG - 3’ for construct -65). The 3’ primers were designed 
with a SmaI site that was identical for all of the constructs (5’- 
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GCGTGGTGTGAGGGTTTC - 3’). These amplified fragments were initially ligated into 
the pUC19 vector and then cloned into the SacI and SmaI sites of the pGL3-Basic. 
A site-directed mutagenesis construct (construct IR2-Mut) was prepared by using 
overlap PCR. In initial step of overlap PCR, the left arm of the PCR product was 
generated from the wild type template, using the same sense primer as deleted construct -
414 and the antisense primer (5’-GCAAGCTCAGAACTCCCCTAAAATGG-3’) 
containing desired base changes corresponding to the CAR binding site of the 
hSULT2A1 promoter. Similarly, the right arm of the PCR product was generated using 
the sense primer (5’-CCATTTTAGGGGAGTTCTGAGCTT GC-3’) containing the 
mutant oligo sequence. The antisense primer was the same as deleted construct -414. 
Amplified DNAs were gel-purified, and construct -414 sense and antisense primers were 
used to splice the left arm and right arm DNA products by overlap PCR. The PCR 
product was initially ligated to pUC19 vector and then subcloned to the upstream of the 
luciferase gene in pGL3-Basic vector at SacI and SmaI sites. DNA sequencing at the 
Oklahoma State University core facility verified all constructs. 
 
3.9 Transfections and Reporter Gene Assays in Hep G2 and Caco-2 Cells 
Hep G2 and Caco-2 cells (ATCC, Manassas, VA) were seeded to 24 well plates 
one day before transfection. Cell culture medium was replaced with 5% charcoal stripped 
FBS medium just before transfection when the cells reach 70% confluence. Both Hep G2 
and Caco-2 cells were seeded onto a 24-well plate at 2 x 105 cells/well and transfected 
after 16 h with 100 ng of reporter plasmid, 50 ng of nuclear receptor expression vectors, 
and 10 ng (50 ng for Hep G2 cells) of the pRL-TK plasmid (Promega, Madison, WI), 
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with 5% charcoal stripped FBS.  The transfection agents were added to a total volume 
containing 98 μl of Opti-MEM and 2 μl of Lipofectamine™ 2000 (Invitrogen, Carlsbad, 
CA). In the CAR and VDR competition experiment, the nuclear receptor VDR was fixed 
as 50 ng and the CAR was gradually increased to 50 ng. The pRL-TK plasmid, which 
expresses Renilla luciferase, was used as an internal standard for transfection assay. The 
pUC19 vector DNA was used as an empty vector to keep the total transfected DNA at a 
fixed value. CAR, VDR and RXRα nuclear receptor agonists were added with fresh 5% 
charcoal stripped FBS 6 hours after transfection. The final concentration of these agonists 
is: MTX, 0.1 μM; CITCO, 50 nM; VD3, 1 μM; 9 cis-retinoic acid, 1 μM; and 0.1% 
(V/V) ethanol. Cells were collected 48 h after transfection and firefly and Renilla 
luciferase activities were measured using the Dual-Luciferase® Reporter Assay System 
(Promega, Madison, WI). Each experiment was repeated three times and each test was 
performed in duplicate. Results are given as means + S.E. 
 
3.10 CAR RNA Interference in Caco-2 Cells 
Caco-2 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with 20% fetal bovine serum (FBS) to about 40% confluence. Just before 
transfection, the cell culture medium was replaced with 5% charcoal stripped FBS which 
contain reduced level of hormone that might cause induction effect of target gene. The 
siRNA targeting hCAR (siRNA ID: 5535 and the siRNA negative control was chemically 
synthesized by Ambion (Austin, US). The transfection agents with a total volume of 300 
μl of Opti-MEM and 3 μl of Lipofectamine™ 2000 were added to Caco-2 cells according 
to the manufacturer's instructions in 6-well plates containing 125 nM siRNA per well. 
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Forty eight hours after transfection, cells were harvested for RNA analysis. For dual 
luciferase assay, plasmid DNA was first transfected into Caco-2 cells and siRNA was 
transfected 6 hours later with refreshed 5% charcoal stripped FBS medium. Cells were 
collected 48 h after transfection and firefly and Renilla luciferase activities were 
measured using the Dual-Luciferase® Reporter Assay System. 
 
3.11 Quantitative Real-Time PCR 
Total RNA was prepared from MTX, CAR, or CAR interference RNA treated 
Caco-2 cells. Superscript II (Invitrogen) reverse transcriptase with 50 to 100 ng of total 
RNA was used to synthesize cDNA, and 1 µl of reverse-transcribed product served as the 
template in polymerase chain reactions. Real-time PCR was performed using QuantiTect 
SYBR Green PCR kit (Qiagen, Valencia, CA) following the manufacturer’s instruction. 
Primers were designed with Primer Express as follow: ACTBF321: 5’- 
AGAAAATCTGGCACCACACC -3’, ACTBR462: 5’-
GGGGTGTTGAAGGTCTCAAA -3’,  
GI,L5016088; hSULT2A1F163: 5’- TGAGTTCGTGATAAGGGATGAA -3’, 
hSULT2A1R294: 5’- CAGATGGGCACAGATTGGAT -3’, GI, 29540544; hCARF959: 
5’- CTTCTCTCCTGACCGACCTG -3’, hCARR1089: 5’- 
TCGCATACAGAAACCGATCC -3’, GI: 32189358. Real-time PCR was performed on 
ABI PRISM 7500 (Applied Biosystems, Foster City, CA). Initially, regular PCR products 
were purified with GENECLEAN Turbo (Qbiogene, Carlsbad, CA) for constructing 
standard curves (10–108 copies). A standard curve was plotted with the threshold cycle 
(CT) vs the logarithmic value of the gene copy number. The gene copy number of 
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unknown samples was generated directly from the standard curve by the software 
Sequence Detector 1.7. At least two repeats were run for each sample; each experiment 
was repeated 3 times. All gene copy numbers were normalized to human beta actin 
mRNA. 
 
3.12 Electrophoretic Mobility Shift Assay (EMSA) and Super Shift Assay 
EMSA was performed using digoxigenin-11-ddUTP labeled oligonucleotides 
which contain the IR2 element DF-191: 5’- 
GGAACGCAAGCTCAGATGACCCCTAAAATGG -3’ or DF-191m: 5’ –
GGAACGCAAGCTCAGAACTCCCCTAAAATGG -3’ (mutated bases underlined). A 
standard gel shift binding reaction (20 μl) contained 20 mM Hepes, pH 7.6, 1 mM 
EDTA, 10 mM (NH4)2 S04, 1 mM DTT, 0.2 % (v/v)Tween 20, , 30 mM KCl, lμg poly 
[d(I-C)], 1 μg poly L-lysine and 5 μg Caco-2 nuclear extract. Reactions were incubated at 
room temperature for 20 min after the addition of double stranded oligonucleotide probe 
(0.4 ng). Competitions were performed with 125-fold molar excess of unlabeled 
oligonucleotides. The nuclear extract was pre-incubated with the antibody at room 
temperature for 20 min before addition of the DNA probe in the supershfit assay. 
Antibodies to MB67 (C-20): sc-8541 and RXRα (D-20): sc-553 X were from Santa Cruz 
Biotechnology (Santa Cruz, CA). The protein-DNA complexes were resolved on a pre-
electrophoresed 5% native polyacrylamide gel in 0.5× TBE (45 mM Tris borate, 1 mM 
EDTA) at room temperature and then blotted to a positively charged nylon membrane. 
The DIG labeled oligonucleotides were visualized by an enzyme immunoassay using 
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anti-Digoxigenin-AP, Fab-fragments and the chemiluminescent substrate CSPD. The 
generated chemilunimescent signals are recorded on X-ray film. 
 
3.13 Statistical Analysis 
 Sulfotransferase activity and luciferase activity were expressed as median ± SE 
(standard error). MTX and nuclear receptors effects on hSULT2A1 in reporter gene assay 
were analyzed for significance by one-way ANOVA (Dunnett’s analysis for all 
treatments with control). MTX time- and concentration-dependent cytotoxicity to Hep G2 
and Caco-2 cells and MTX time- and concentration-dependent inducing ability to 
hSULT2A1 promoter activity in Caco-2 cells were analyzed by two-way ANOVA. All 
statistical analyses were done with the SAS statistical computer software (SAS 9.1). In all 







4.1 MTX Induction of hSULTs in Hep G2 and Caco-2 Cells 
4.1.1 MTX Induction of hSULT1A1 in Hep G2 and Caco-2 Cells 
The effect of MTX on hSULT1A1 was evaluated by enzyme assay, western blot, 
and RT-PCR. Figure 4.1.1 demonstrates that MTX can induce hSULT1A1 at both the 
protein and mRNA level in Hep G2 cells. MTX induction of hSULT1A1 was 
concentration-dependent. 2-Naphthol sulfation activity significantly increased in response 
to low doses of MTX treatment (Figure 4.1.1A). The hSULT1A1 induction reached the 
maximum level when MTX concentration was 0.2 μM, followed by a decreased 
induction with increasing MTX concentrtion.  Treatment of Hep G2 cells for 10 days 
with 0.2 μM MTX increased the sulfation activity up to 2.5 fold. In Hep G2 cells, the 
Western blot (Fig 4.1.1B) and RT-PCR (Figure 4.1.1C) results agree with enzyme 
activity assays. In contrast, MTX did not alter hSULT1A1 expression in Caco-2 cells as 
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Figure 4.1.1 Effects of MTX treatment on hSULT1A1 activity in Hep G2 cells and 
Caco-2 cells 
For A and D: Specific activity (SA) was expressed as nanomoles or picomoles per minute 
per milligram of protein. For B and E: each column of the densitometry corresponds to 
each lane of Western blot. For C and F: each column of the densitometry corresponds to 
each lane of RT-PCR, human β-actin was used as the internal control for RT-PCR. 
Values of densitometry analysis (for both Western blot and RT-PCR) were divided by the 
control value and the division factors were plotted. The control value was calculated as 1. 
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4.1.2 MTX Induction of hSULT1A3 in Hep G2 and Caco-2 Cells 
hSULT1A3 was induced in both Hep G2 cells and Caco-2 cells after treatment 
with MTX. Western blot results of Hep G2 cells showed that MTX induction of 
hSULT1A3 increased with MTX concentrations up to 0.2 μM followed by a decreased 
induction with increasing MTX concentration (Figure 4.1.2A). The RT-PCR (Figure 
4.1.2B) results agree with Western blot in Hep G2 cells. Different from Hep G2 cells, 
MTX induction of hSULT1A3 in Caco-2 cells increased with increasing concentration of 
MTX up to 5 μM. Western blot results agree with RT-PCR results, indicating that the 



























































































Figure 4.1.2 Effects of MTX treatment on hSULT1A3 activity in Hep G2 cells and 
Caco-2 cells. 
For A and C: each column of the densitometry corresponds to each lane of Western blot. 
For B and D: each column of the densitometry corresponds to each lane of RT-PCR, 
human β-actin was used as the internal control for RT-PCR. 
Values of densitometry analysis (for both Western blot and RT-PCR) were divided by the 
control value and the division factors were plotted. The control value was calculated as 1. 
 
 44
4.1.3 MTX Induction of hSULT2A1 in Hep G2 and Caco-2 Cells 
hSULT2A1 was also induced in both Hep G2 and Caco-2 cells after treatment 
with different concentration of MTX.  MTX induces hSULT2A1 in both Hep G2 and 
Caco-2 cells in a concentration-dependent manner (Figure 4 A, B, D, and E). DHEA 
sulfation activity in Hep G2 cells increased by 1.7-fold and hSULT2A1 mRNA content 
increased by 3.6-fold after treatment with 0.2 μM MTX. In Caco-2 cells, DHEA sulfation 
activity increased 2-fold and hSULT2A1 mRNA increased 1.9-fold after treatment with 1 
μM MTX. For both Hep G2 and Caco-2 cells, enzyme assay, Western blot, and RT-PCR 
results are all in agreement. MTX induction of hSULT2A1 is at the transcriptional level 
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Figure 4.1.3 Effects of MTX treatment on hSULT2A1 activity in Hep G2 cells and 
Caco-2 cells 
For A and D: Specific activity (SA) was expressed as picomoles per minute per milligram 
of protein. For B and E: each column of the densitometry corresponds to each lane of 
Western blot. For C and F: each column of the densitometry corresponds to each lane of 
RT-PCR, human β-actin was used as control for RT-PCR. 
Values of densitometry analysis (for both Western blot and RT-PCR) were divided by the 
control value and the division factors were plotted. The control value was calculated as 1. 
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4.1.4 MTX Induction of hSULT1E1 in Hep G2 and Caco-2 Cells 
MTX effect to hSULT1E1 was evaluated in both Hep G2 and Caco-2 cells. 
Enzyme assay (Figure 4.1.4A) and Western blot (Figure 4.1.4B) results demonstrated that 
MTX induce hSULT1E1 in Hep G2 cells with maximum induction at 0.04 μM MTX.  












































































Figure 4.1.4 Effects of MTX treatment on hSULT1E1 activity in Hep G2 cells and Caco-
2 cells 
For A: Specific activity (SA) was expressed as picomoles per minute per milligram of 
protein. For B and C: each column of the densitometry corresponds to each lane of 
Western blot.  
Values of densitometry analysis for both western blots were divided by the control value 
and the division factors were plotted. The control value was calculated as 1. 
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4.1.5 Folic Acid Inhibition of MTX Induction of hSULT1A1 in Hep G2 Cells 
MTX is a folate antagonist. In this investigation, folic acid was used to determine 
its effect on MTX induction of hSULTs. Our results suggested that MTX induction of 
hSULTs could be inhibited by high concentrations of folic acid. Figure 4.1.5 
demonstrates that the induction of hSULT1A1 by MTX in Hep G2 cells can be inhibited 
by high concentrations of folic acid. Folic acid induction of hSULTs in Hep G2 is not 
significant. When incubated together with MTX, folic acid can suppress hSULT1A1 
induction. The suppression was concentration-dependent. The MTX induction activity 
was only partially inhibited when the folic acid concentration was 100 μM. When the 
folic acid concentration reached 1000 μM, the induction of SULT1A1 was almost totally 
inhibited (Figure 4.1.5A).   The results were supported by Western blot (Figure 4.1.5B) 
and RT-PCR (Figure 4.1.5C). 
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Figure 4.1.5 hSULT1A1 protein and mRNA analysis in folic acid and MTX treated Hep 
G2 cells  
For A: Specific activity (SA) was expressed as nanomoles per minute per milligram of 
protein. For B: each column of the densitometry corresponds to each lane of Western 
blot. For C: each column of the densitometry corresponds to each lane of RT-PCR; 
human β-actin was used as the internal control for RT-PCR. 
Values of densitometry analysis (for both Western blot and RT-PCR) were divided by the 




4.1.6 Folic Acid Inhibition of MTX Induction of hSULT1A3 in Hep G2 Cells 
MTX induction of hSULT1A3 in Hep G2 cells was inhibited by the addition of 
folic acid (Figure 4.1.6). Western blot results (Figure4.1.6A) showed that both 100 and 
1000 μM folic acid completely suppressed hSULT1A3 induction in the presence of 0.1 
μM MTX. RT-PCR results showed that high levels of folic acid increased hSULT1A3 
mRNA expression (Figure 4.1.6B). When added together with MTX, folic acid always 
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Figure 4.1.6 hSULT1A3 protein and mRNA analysis in folic acid and MTX treated Hep 
G2 cells 
For A: each column of the densitometry corresponds to each lane of Western blot. For B: 
each column of the densitometry corresponds to each lane of RT-PCR; human β-actin 
was used as the control for RT-PCR. 
Values of densitometry analysis (for both Western blot and RT-PCR) were divided by the 
control value and the division factors were plotted. The control value was calculated as 1. 
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4.1.7 Folic Acid Inhibition of MTX Induction of hSULT2A1 in Hep G2 Cells 
MTX induction of SULT2A1 was inhibited by 100 μM folic acid (Figure 4.1.7), 
whereas 1000 μM folic acid almost completely inhibited hSULT2A1 induction. 
Enzymatic assay results (Figure4.1. 7A) agree with Western blot results (Figure 4.1.7B). 
hSULT2A1 mRNA expression demonstrated by RT-PCR agrees with protein expression 
levels demonstrated by enzymatic assay and Western blot results (Figure 4.1.7C). This 
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Figure 4.1.7 hSULT2A1 protein and mRNA analysis in folic acid and MTX treated Hep 
G2 cells. 
For A: Specific activity was expressed as picomoles per minute per milligram of protein. 
For B: Each column of the densitometry corresponds to each lane of Western blot. For C: 
each column of the densitometry corresponds to each lane of RT-PCR; human β-actin 
was used as control for RT-PCR. 
Values of densitometry analysis (for both Western blot and RT-PCR) were divided by the 
control value and the division factors were plotted. The control value was calculated as 1. 
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4.1.8 Folic Acid Inhibition of MTX Induction of hSULT1E1 in Hep G2 Cells 
MTX induction of hSULT1E1 was inhibited by folic acid (Figure 4.1.8). The 
inhibition of hSULT1E1 was also folic acid concentration-dependent. The Western blot 
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Figure 4.1.8 hSULT1E1 sulfation activity and western blot analysis in folic acid and 
MTX treated Hep G2 cells 
For A: Specific activity (SA) was expressed as picomoles per minute per milligram of 
protein. For B: each column of the densitometry corresponds to each lane of Western 
blot.  
Densitometry value of western blot was divided by the control value and the division 
factors were plotted. The control value was calculated as 1. 
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4.2 MTX Cytotoxicity  
 
4.2.1 The Cytotoxicity of MTX to Caco-2 Cells 
MTT assay was used to analyze the metabolic activity of drug treated cells based 
on the ability of mitochondrial succinate-tetrazolium reductase system to convert the 
yellow substrate to a blue formazan dye.  Here, we use MTT assay to determine the 
cytotoxicity of MTX to Caco-2 and Hep G2 cells. Figure 4.2.1 shows the cytotoxicity of 
MTX to Caco-2 cells in a time- and concentration-dependent manner. At low 
concentration such as 0.02 μM, MTX did not show any significant cytotoxicity even 
when the Caco-2 cells were exposed to MTX for 8 days. At the highest concentration of 
12.5 μM, MTX showed significant toxicity in as early as two days. MTX cytotoxicity 
increased with both concentration and time.  In general, our data suggests that MTX is 
not obviously cytotoxic to Caco-2 cells below 0.1 μM within one week. The estimated 
IC50s to MTX for Caco-2 cells are: 2 days (34 μM), 4 days (17 μM), 6 days (11 μM), 
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Figure 4.2.1 Time- and concentration-dependent cytotoxicity of MTX to Caco-2 cells  
Caco-2 cells were treated with different concentrations of MTX for 2, 4, 6 or 8 days. 
MTT assay was conducted to test the metabolic activity of the treated cells. The y-axs 
represents the metabolic activity of the cells. The OD value of the control cells (cells 
incubated with physiological saline solution) was taken as 1.0 and the ratio of the treated 
cells divided by the control represent the metabolic activity of the treated cells. Values 
less than 1 reflect reduced cell viability. The histograms with standard error are averaged 
values from four independent experiments; each treatment was done in quadruplicate. *, p 
< 0.05 and **, p < 0.01 compared with control in each defined time. 
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4.2.2 The Cytotoxicity of MTX to Hep G2 Cells 
MTX cytotoxicity to Hep G2 cells (figure 4.2.2) is very similar to that of Caco-2 
cells and is time- and concentration- dependent. The only difference is that Hep G2 cells 
are less sensitive to MTX. When exposed to MTX for just 2 days, the treated Hep G2 
cells did not show significant decreased cell viability even with the highest concentration 
of 12.5 μM. In contrast, the Caco-2 cells showed significant cytotoxity when the MTX 
concentration reached 0.5 μM. Compared with Caco-2 cells, Hep G2 cells are more 
resistant to MTX. The estimated IC50s to MTX for Hep G2 cells at various exposure 
times are: 2 days (54 μM), 4 days (29 μM), 6 days (18.5 μM), and 8 days (16.5 μM). In 
our studies, MTX induction of hSULT at both mRNA and protein level in both Hep G2 
and Caco-2 cells, and the induction reaches its maximum around 0.2 μM as described in 
part 3.1. MTX induction activity decreased when its concentration reached above 0.2 
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Figure 4.2.2 Time- and concentration-dependent cytotoxicity of MTX to Hep G2 cells 
 
Hep G2 cells were treated with different concentrations of MTX for 2, 4, 6, or 8 days. 
MTT assay was conducted to test the metabolic activity of the treated cells. The y-axes 
represents the metabolic activity of the cells. The OD value of the control cells (cells 
incubated with physiological saline solution) was taken as 1.0, and the ratio of the treated 
cells divided by the control represents the metabolic activity of the treated cells. Values 
less than 1 reflect reduced cell viability. The histograms with standard error are averaged 
values from four independent experiments. Each treatment group was done in 
quadruplicate, *, p < 0.05 and **, p < 0.01 compared with control in each defined time. 
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4.2.3 MTX Transactivation of hSULT2A1 Promoter Regulated Luciferase Expression 
4.2.3.1 Construction of hSULT2A1 Promoter Reporter Vector 
To explore the molecular mechanism of hSULT2A1 expression, hSULT2A1 5’-
flanking region (-1463 to +48) was generated by PCR with gene specific primers  
(Otterness, Her et al. 1995; Duanmu, Locke et al. 2002) using genomic DNA extracted 
from Hep G2 cells. Our sequence of the PCR product was essentially the same as the 
published sequence (L36191 and U13056) (Otterness, Her et al. 1995). The generated 
DNA sequence was inserted into pGL3-Basic vector (Promega) at the MluI and XhoI 
sites.  
 
4.2.3.2 MTX Transactivation of hSULT2A1 Promoter Regulated Luciferase Expression in 
Caco-2 cells 
To investigate the effect of MTX to the promoter activity of hSULT2A1, the 
constructed luciferase reporter vector containing hSULT2A1 promoter sequence was 
transfected into Caco-2 cells; the transfected Caco-2 cells were treated with different 
concentrations of MTX for different times. The data in figure 4.2.3 shows that MTX 
induce hSULT2A1 promoter activity in a time- and concentration-dependent manner. At 
a fixed concentration of MTX, the promoter activity increased with incubation time. At 
any fixed time (from 12 hours to 48 hours), the promoter activity increased when MTX 
concentration drop below 2.5 μM. The promoter activity starts to decrease when the 
MTX concentration reached between 2.5 and 12.5 μM. These results agree with our 





















Figure 4.2.3 Time- and concentration-dependent induction of hSULT2A1 promoter 
activity by MTX in Caco-2 cells 
Luciferase reporter gene regulated by 5'-flanking sequence of hSULT2A1 was transfected 
into caco-2 cells. 6 hours later, the transfection medium was replaced by serum free 
medium and treated with different concentration of MTX.  pRL-TK (Promega) was used 
as the internal control for transfection assay. Dual-luciferase activities were measured 
after 12, 24, 36 or 48 hours of MTX treatment. The histograms with standard error are 
averaged values from three independent experiments; each test was done in duplicate.  *, 








4.3 hSULT2A1 is transcriptionally Regulated by CAR 
4.3.1 CAR Transactivation of hSULT2A1 Promoter in Caco-2 Cells 
To explore the molecular mechanism involved in hSULT2A1 regulation, we 
cloned the promoter sequence of hSULT2A1 and inserted it into the pGL3-Basic vector. 
The constructed reporter vector was transfected into Caco-2 cells. CITCO (6-(4-
chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde  O-(3,4-dichlorobenzyl)oxime) 
is a well-known agonist of hCAR reported to induce human CYP2B6 in human primary 
cells (Maglich, Parks et al. 2003). Results shown in Figure 4.3.1 demonstrate that CITCO 
can also induce hSULT2A1 in Caco-2 cells. The induction activity of CITCO to 
hSULT2A1 is similar to that of MTX. Transfection of CAR or RXRα alone caused 2 fold 
activation of hSULT2A1 promoter. For both CITCO and MTX, when the drug treated 
cells were cotransfected with CAR, the luciferase activity increased 4 fold. 
Cotransfection of CAR and RXRα together with 9-cis-retinoic acid (9-cis-RA) and 
CITCO caused the activation of hSULT2A1 more than 8 fold. This strongly suggests that 
the CAR transactivation occurs via formation of a heterodimer with RXRα. This agrees 
with P-450s and other drug metabolizing enzymes induction mechanisms: most nuclear 
receptors, which can induce drug-metabolizing enzymes, form heterodimers with RXRα. 
When CITCO was replace by MTX, the promoter activity of hSULT2A1 was also 
significantly induced. This suggests that MTX can function as an agonist of CAR and 
induce the expression of hSULT2A1. All these results suggest a functional DNA cis-
element is present in the cloned promoter sequence of hSULT2A1, and it can be activated 

































Figure 4.3.1 Effect of CAR and RXRα on CITCO and MTX Induction of hSULT2A1 
promoter activity in Caco-2 cells 
Luciferase construct containing 5'-flanking sequence of hSULT2A1 were transfected into 
Caco-2 cells together with hCAR and hRXRα. The transfected cells were treated with 
MTX, CITCO, retinoic acid and/or alcohol. pRL-TK was used as the internal control for 
the transfection assay. Fold inductions were calculated relative to the promoter activity in 
vehicle-treated cells. Concentrations used: CAR (25 ng), RXRα (25 ng), MTX (100 nM), 
CITCO (100 nM) and 9-cis-RA (1 μM). Dual-luciferase activities were measured 
according to the manufacturer's recommendations. The histograms with standard error are 
averaged values from three independent transfections; each independent transfection was 
performed in duplicate.  *, p < 0.05; and **, p < 0.01 compared with vehicle (alcohol) 
control samples 
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4.3.2 The Expression of hSULT2A1 is Closely Related to the Expression of CAR 
We designed the RNA intereference experiment to confirm the positive role of 
CAR in hSULT2A1 regulation. We employed CAR specific siRNA (provided by 
Ambion Inc.) in both reporter gene assay and endogenous study. The results showed in 
figure 4.3.2 demonstrate that CAR was a transcription factor involved in the up-
regulation of hSULT2A1.  
In the reporter gene assay experiment, we transfected the hSULT2A1 promoter 
regulated luciferase reporter vector into Caco-2 cells; the luciferase expression of control 
cells reflected the basal promoter activity of hSULT2A1. Upon the transfection of CAR 
specific siRNA, the luciferase expression reduced to approximately 50% (Figure 2A) 
compared with the control cells. This strongly suggests that CAR was involved in the 
transcriptional regulation of hSULT2A1. As previously discussed, the cotransfection of 
CAR can induce hSULT2A1 promoter activity 2 fold; this induction can also be partly 
knocked down by the CAR specific siRNA.  
We use real-time PCR method to check the mRNA copy number of CAR and 
hSULT2A1 in Caco-2 cells. The results showed in figure 2B and figure 2C indicate that 
both the transfection and the RNA interference work well. The control cells show in 
figure 2B contain very low copy number of CAR. When the CAR expression vector was 
transfected, the mRNA copy number of CAR dramatically increased. The mRNA copy 
number of CAR decreased about 70% when the CAR transfected cells were treated with 
CAR specific siRNA. This indicates that the luciferase expression in figure 2A is closely 
related to the mRNA copy numbers of CAR. When the mRNA amount of CAR 
increased, the promoter activity of hSULT2A1 increased; when the mRNA amount of 
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CAR decreased, the promoter activity of hSULT2A1 decreased. Figure 2C shows the 
mRNA copy number of hSULT2A1 is closely related to the expression of CAR. When 
the mRNA amount of CAR increased through the transfection of CAR, the mRNA copy 
number of hSULT2A1 also increased. When the CAR mRNA level was knocked down 
by the siRNA, the hSULT21 expression level also decreased. These results strongly 
support that CAR is a transcription factor that can up-regulate the expression of 
hSULT2A1. 
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Figure 4.3.2 Effect of RNA interference of CAR on hSULT2A1 transcriptional activity. 
Figure A. The luciferase reporter vector regulated by the hSULT2A1 promoter was 
transfected into Caco-2 cells, and dual luciferase activity was measured according to 
manufacture’s recommendation. Figure 4.3.2B and figure 4.3.2C, Caco-2 cells were 
transfected with CAR expression vector and CAR specific siRNA was transfected 6 
hours later. The transfected cells were harvested after 48 hours and analyzed for real-time 
PCR with gene specific primers for human β-actin, CAR and hSULT2A1 as described in 
"Materials and Methods." Each treatment group was analyzed in triplicate and the data 
shown were averaged of three independent experiments.  
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4.3.3 DNA Response Element Responsible for CAR/RXRα Heterodimer Mediated 
Induction of hSULT2A1 
 To identify the DNA response element involved in hSULT2A1 regulation, 
functional promoter assay with progressively deleted 5’ flanking region of hSULT2A1 
promoter sequence was performed. Deletion analysis results are shown in Figure 4.4.3. 
The results suggest that the deletion between -1463 and -713 did not significantly change 
the promoter activity. Deletion from -731 to -414 decreased the basal promoter activity, 
but the promoter activity was still fairly high. Deletion between -414 and -188 (C-F) did 
not significantly change the promoter inducing ability caused by CAR and MTX.  When 
the promoter sequence was deleted to 130 bp upstream of the transcription start site, the 
reporter vector almost completely lost its induction mediated by CAR and MTX. This 
suggests that the key element responsible for the promoter activity is located between -
188 and -130, although the DNA cis-acting regulatory elements located between -1463 
and -713 may also be necessary for the full responsiveness of CAR-mediated MTX 
induction of hSULT2A1. 
 Careful analysis of the DNA sequence (Figure 4.4. 4) between -188 and -130 
revealed a hexameric core sequence AGCTCA between -186 and -181. Two base pairs 
downstream from this half-site show the imperfect inverted repeat sequence TGACCC (-
178 to –173). This forms an imperfect inverted repeat motif IR2 (-
186AGCTCAGATGACCC-173). This IR2 sequence may be the element binding site of 
the CAR/RXRα heterodimer.  
Mutation results shown in Figure 4.4.5 demonstrate that this IR2 element is the 
sequence responsible for induction of hSULT2A1 via CAR/RXRα. Compared with the 
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control (Figure 4.3.5), the mutated 5’-flanking region of hSULT2A1 (-414 to +48) lost 
about 50% of its basal luciferase activity. When treated with MTX or CAR, the mutated 
promoter can not be activated by CAR or MTX. Interestingly even, the transfected CAR 
can cause the inhibition of the basal luciferase activity. This suggests that there may be 

















































































































































Figure 4.3.3 Deletion analysis of hSULT2A1 promoter  
Figure A, schematic diagram of deleted hSULT2A1 promoter constructs. Figure B-I, 
transactivation of deleted promoter constructs by CAR and MTX. The constructed pGL3-
Basic vectors include hSULT2A1 5’-flanking region from the number indicated in the 
figure A to +48. Transfected Caco-2 cells were treated with MTX for 48 h as indicated. 
50 ng CAR was used for transfection. 100 nM MTX was used for treatment. Promoter 
activity is expressed as normalized luciferase activity. The histograms with standard error 
are averaged values from three independent transfections; each independent transfection 




-      Rat 273TCTGAAAGCT AAATTGCATT AGAAGATATT TTAAATTATC CTGCAGTTTT ATGTCCTATT 
    Mouse-272TCTGAAAGCT AAATTATATT ACTAGACATT TTAAATTAAC TTGCATTTCT ATGTCCTATT 
     Human-275ACCTTAAGAA ATAAATTCAC CCATATTATC AAAAAAAATA TTTGTCCTCG TGTTTGTTAT 
 Consensus  tCtgaAAGct AaAtt.tatt acaagatATt ttAAAttAtc tTgca.tTct atgTccTatT 
 
     IR0            IR2 
 
       Rat  ACT-TCTTAC TGAGTTTCTG TTTGGGGGTC ATGAACTTGG GCTCACAAAT GCTGCAGAAT 
     Mouse  ACG-TCTTCC TGAGTCTCTG ATTTGGGGTC ATGAACTTGG TCTCACAGGT TGTACAGAAT 
     Human  TCGATCTTGC AGT-TCACTC --------TC AGGAACGCAA GCTCAGATGA CCCCTAAAAT 
 Consensus  aCg.TCTT.C tGagTctCTg .tt.ggggTC AtGAACttgg gCTCAcA.gt .ct.cAgAAT 
 
       Rat  GTTCTTTGTG TGA-GTTGAA ATTGCTCAA- TACAA-TAAC CTTTGACTGT GTGTTACAAT 
     Mouse  GTTATTTGTA CAACTTTAAA ATTTCTCAA- TAGAG-TAAC CTTTCACTGT AGGTGACAAT 
     Human  GGTCTCTAGA TAAGTTCATG ATTGCTCAAC ATCTTCAATC TTTTGAGTAT GGGTCACATT 
 Consensus  GtTcTtTgta taA.tTtaaa ATTgCTCAA. taca..tAaC cTTTgAcTgT ggGT.ACAaT 
 
       Rat  ATTTATTTAT TCCT-ATCAG TAGTTAGTTT CA-CAA---- ----CAGACT AGAG-AATGT 
     Mouse  ATTTATTTCT -CCACATCAG TAAATA-TTT CA-CAA---- ----CACATA AGAG-AATGT 
     Human  ATACCTCTCT TTATCAGCAA GTAAACTTTA CAACAAACAT GTGACATGCT GGGACAAGGT 
 Consensus  ATttaTtTcT tcctcAtCAg taaata.TTt CA.CAA.... ....CA.act aGag.AAtGT 
 
       Rat  TAATGATTCT TTTAACTCCA CTATAAAT-C TTACCTCTCA GCATTTGCTA TAAGC+6 
     Mouse  TAATGATT-T TTTACCTGCA CTATAAAT-C TTACCTCTCA GCATTTGTTA TAAGT+6 
     Human  TAAAGATCGT TTTATCCTTG CTGTAAAAGC TGATCT-GC- -CTGTAGCTG CCA+6 
 Consensus  TAAtGATt.T TTTA.Ct.ca CTaTAAAt.C TtAcCTctCa gCatTtGcTa taAg.
 
 
Figure 4.3.4 Sequence alignment of rat, mouse, and human SULT2A1 promoter regions. 
MultAlin program was used for the alignment of rat (GenBank accession no. M29301), 
mouse (Echchgadda, Song et al. 2004), and human (GenBank accession no. U54701) 

















































Figure 4.3.5 Point mutation analysis of the IR2 DNA cis-element 
Mutated 5’-flanking region of hSULT2A1 (-414 to +48) as shown in the figure was 
inserted into pGL3-Basic vector. The constructed reporter vector and CAR were 
transfected into Caco-2 cells and treated with MTX. pRL-TK was used as internal control 
for transfection assay. Dual-luciferase activities were measured according to the 
manufacturer's recommendations. The histograms are averaged values from three 





4.3.4 Electrophoretic Mobility Shift Assay (EMSA) and Super Shift Assay for the 
Interaction of CAR and RXRα with IR2 Element 
Electrophoretic mobility shift assay (EMSA) and super shift assay were used to 
prove the interaction of CAR and RXRα with the identified IR2 element in the promoter 
region of hSULT2A1. The 31 bp oligonucleotide (5’ -GGA ACG CAA GCT CAG ATG 
ACC CCT AAA ATG G - 3’) which include the IR2 element and its mutant (5' - GGA 
ACG CAA GCT CAG AAC TCC CCT AAA ATG G - 3’) were ordered from IDT. Both 
the IR2 sequence and IR2 mutant sequence were labeled with digoxigenin (DIG) 
molecule. The DIG molecule labeled oligonucleotides was visualized by an enzyme 
immunoassay using anti-digoxigenin-AP, Fab-fragments and the chemiluninescent 
substrate CSPD. Experimental results showed that nuclear extract from Caco-2 cells 
caused the IR2 probe shift (Figure 3.3.3 lane 2). 125 fold excess of cold IR2 sequence 
inhibited this shift (lane 3) and mutated cold IR2 probe (125 fold) did not inhibit this shift 
(lane 4). Also, mutated IR2 labeled probe was not shifted by the nuclear extract (lane 5). 
These results strongly suggest that certain nuclear receptors can bind to the IR2 element. 
Super shift assay (lane 6 and 7) results showed that hCAR and hRXRα antibodies caused 
the nuclear extract shift to disappear (or tremendously decrease). The super shift band 
was not found. There are two possible causes of the disappearance of the shift band. The 
antibody may cause the corresponding receptor-oligonucleotide complex precipitate; 
therefore not appearing in the gel or running into the gel. A second possibility is that the 
interaction between antibody and nuclear receptor disables the receptor from binding to 
the IR2 element. The super shift assay results suggest that CAR and RXRα (or their 



















Figure 4.3.6 EMSA of Caco-2 nuclear extract and super shift of CAR and RXRα. 
Figure A, Gel shift assay of IR2 sequence. The labeled IR2 wild type sequence (lane 1) or 
mutated IR2 sequence (lane 5) were incubated with Caco-2 nuclear extract (lane 2) for 20 
minutes at room temperature to form possible DNA protein complexes. 125-fold excess 
of cold competitors was added to test the specificity of the complexes (lane 3, 4). Figure 
B, super shift assay of Caco-2 nuclear extract. Antibody specific to CAR (lane 6) and 
RXRα (lane 7) was added to the nuclear extract and incubated for 20 minutes at room 
temperature before the shift reaction. 
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4.4 Interaction among CAR, PXR, and VDR for the Regulation of hSULT2A1 
4.4.1 Interaction of CAR, PXR, and VDR with the IR2 DNA cis-element 
As discussed in section 4.3, the IR2 element located at -186 /-173 of hSULT2A1 
promoter region plays a very important role in MTX induction of hSULT2A1. We found 
several nuclear receptors that can interact with the IR2 element and regulate the activity 
of hSULT2A1. When we transfected the Caco-2 cells with reporter vector which was 
regulated by the wild type hSULT2A1 promoter vector, we found the cotransfection of 
CAR and VDR can significantly increase the promoter activity of hSULT2A1 compared 
with the control cells which was treated with transfection reagent only. The 
cotransfection of PXR significantly inhibits the promoter activity of hSULT2A1. Then 
we mutated the IR2 sequence through overlap PCR as described in materials and 
methods. The mutated promoter sequence regulated luciferase reporter vector was 
transfected into Caco-2 cells. The basal luciferase activity regulated by this mutated 
promoter sequence decreased about 1 fold compared with wild type promter sequence 
(figure 4.4.1). Most interestingly, all three nuclear receptors inhibit the luciferase activity 
when they cotransfected with the reporter vector regulated by the mutated IR2 element. 
This mean that CAR and VDR reverse their up-regulation effect and start to repress the 
mutated promoter activity of hSULT2A1, and PXR further represses this mutated 
promoter activity. These data indicate all the three nuclear receptors can interact with the 
IR2 element. CAR and VDR induce the activity of hSULT2A1, and PXR inhibits the 
activity of hSULT2A1. 
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Figure 4.4.1 CAR, VDR, and PXR involved in the transcriptional regulation of 
hSULT2A1 promoter activity.  
A, DNA sequence of wild type IR2 DNA response element and mutated IR2 DNA 
response element.  B, Wide type or mutated 5’-flanking region of hSULT2A1 (-414 to 
+48) was inserted into pGL3-Basic vector as described under "materials and methods." 
Dual luciferase activities were determined according to the manufacturer's 
recommendations. pRL-TK was used as the internal control for transfection assay.  CAR, 
VDR or PXR were cotransfected with a final concentration of 50 ng per well in a 24 well 
plate. MTX (100 nM and VD3 (50 nM) were added to VDR cotransfected cells. The 
histograms with standard error are averaged values from three independent experiments; 
each independent transfection was performed in duplicate. *p<0.05 and **p<0.01 
compared with control within the same group (either wild type group or mutated group). 
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4.4.2 PXR Inhibition of MTX and CAR Mediated up-regulation of hSULT2A1  
Since PXR inhibits the activity of hSULT2A1 and CAR transactivates the MTX 
mediated induction of hSULT2A1, we want to see if PXR can inhibit the MTX and CAR 
induction of hSULT2A1. Without any treatment of MTX or CAR, PXR can decrease the 
basal luciferase activity 50% compared with the control which received only transfection 
reagent (figure 4.4.2). In the presence of CAR or MTX, PXR can decrease the promoter 
activity of hSULT2A1 induced by MTX, CAR, or MTX together with CAR. Without 
PXR, either MTX or CAR can induce the luciferase activity 2 fold. The luciferase 
activity came down to the control level when PXR was cotransfected. This means PXR 
can repress the induction of hSULT2A1 mediated by MTX or CAR. As previous 
discussed, MTX and CAR together can induce the promoter activity of hSULT2A1 4 
fold, When PXR was cotransfected, the induction come down to only 2 fold. All these 
results indicate that PXR can inhibit the MTX and CAR induction of hSULT2A1. We 
also performed the endogenous induction study for PXR and found that the transfection 
of PXR can repress the expression of hSULT2A1.The endogenous study supported our 
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Figure 4.4.2 PXR inhibition of MTX and CAR induction of hSULT2A1 promoter 
activity. 
Luciferase reporter vector regulated by wild type hSULT2A1 promoter sequence was 
transfected into Caco-2 cells and treated with MTX.  CAR or PXR nuclear receptors were 
cotransfected with a final concentration of 50 ng per well in a 24 well plate. pRL-TK was 
used as internal control for transfection assay. Luciferase expression was determined 
according to the manufacturer's recommendations. The histograms with standard error are 
averaged values from three independent transfections; each independent transfection was 
performed in duplicate. 
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4.4.3 Competition between VDR and CAR for the Promoter Activity of hSULT2A1 
Both VDR and CAR can up-regulate the promoter activity of hSULT2A1, 
therefore, we wanted to see if there is a competition relationship between VDR and CAR. 
Caco-2 cells were transfected with a fixed amount of VDR (50 ng), increasing amounts of 
CAR (from 0 to 50 ng), and the luciferase reporter vector regulated by hSULT2A1 
promoter. The transfected cells were subsequently treated with VD3, MTX, or ethanol 
(vehicle). Cotransfection of increasing amounts of CAR caused a progressive decline in 
the vitamin D responsiveness of the hSULT2A1 promoter and a concomitant 
enhancement in the MTX-mediated induction of this promoter (figure 4.4.3). Because 
CAR shows ligand independent transcriptional activity, the luciferase activity in the 
control cells increasd with the increasing amounts of CAR. In the competition of VDR 
and CAR, hSULT2A1 is more sensitive to CAR because when the CAR concentration 
had just reach 5 ng (the ratio of CAR to VDR is 1:10), VDR started to lose its induction 
ability. These results suggest that VDR and CAR compete for the same DNA response 






























Figure 4.4.3 VDR and CAR compete for the promoter activity of hSULT2A1  
Luciferase reporter vector regulated by hSULT2A1 promoter was transfected into Caco-2 
cells and treated with VD3 or MTX as described.  VDR was cotransfected with a fixed 
amount of 50 ng, and increasing amount of CAR. pRL-TK was used as the internal 
control for the transfection assay. Luciferase expression was determined according to the 
manufacturer's recommendations. The histograms with standard error are averaged values 
from three independent experiments; each independent transfection was performed in 
duplicate. 
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4.5 MTX Time-dependent Endogenous Induction of hSULT2A1 and Synergistic 
Effect with CAR 
4.5.1 MTX Induction of hSULT2A1 in a Time-dependent Manner in Both Caco-2 and 
Hep G2 Cells 
As we discussed in part 4.1, MTX can induce the four main families of hSULTs 
in a concentration-dependent manner in both Caco-2 and Hep G2 cells. To further 
investigate the effect of the time involved in MTX induction, we performed the MTX 
time-dependent experiment and found that MTX induces SULT2A1 in a time-dependent 
manner in both Caco-2 and Hep G2 cells (Figure 4.5.1). When the Caco-2 cells was 
treated with 0.1 μM MTX for 2 days, the mRNA level of hSULT2A1 increased 4 fold 
compared with the control cells. When the MTX exposed time increased to 6 days, the 
mRNA of hSULT2A1 in the treated cells showed 7 fold inductions. The MTX induction 
pattern of hSULT2A1 in Hep G2 cells is similar to Caco-2 cells, the mRNA level of 
hSULT2A1 increased 2 or 4 fold after being treated with MTX for 2 or 6 days. Western 
blot results agree with real-time PCR. hSULT2A1 protein level was induced by MTX in 
a time-dependent manner in both Caco-2 and Hep G2 cells. 
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Figure 4.5.1 Time-dependent induction of hSULT2A1 by MTX in Caco-2 and Hep G2 
cells 
Caco-2 and Hep G2 cells were treated with MTX for 2 days or 6 days. Cells were 
harvested for real-time PCR and for western blot. For A and B: real-time PCR. For C and 
D: a representative of western blot. For E and F: each column of the densitometry 
corresponds to each lane of western blot. Human β-acitin was used as the control for both 
RT-PCR and western blot. The copy number of MTX treated cells divided by the copy 
number of control cells gives the induction fold. The control value was calculated as 1. 
The histograms with standard error are averaged values from three independent 
experiments.  
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4.5.2 CAR Transactivation of MTX Induction of hSULT2A1 in Caco-2 Cells 
Reporter gene assay was used to evaluate the role of CAR involved in the MTX 
induction of hSULT2A1 in Caco-2 cells. Caco-2 cells were transfected with luciferase 
reporter vector regulated by hSULT2A1 promoter sequence. The transfected cells were 
exposed to different concentration of MTX from 8 nM to 50000 nM for 48 hours with or 
without cotransfection of CAR. The data shows in Figure 4.4.2 indicates that MTX can 
induce the promoter activity of hSULT2A1 in a concentration-dependent manner.  This 
agrees well with the endogenous study of MTX induction of hSULT2A1 in Caco-2 cells 
as described in section 4.1. When the Caco-2 cells were cotransfected with CAR, the 
luciferase activity further increased in all MTX concentrations used. CAR always has 
synergistic effect with MTX in hSULT2A1 regulation. This strongly indicates CAR can 































Figure 4.5.2   MTX and CAR induction of hSULT2A1 in Caco-2 cells 
Luciferase reporter vector regulated by hSULT2A1 promoter sequence (from -1463 to 
+48) was transfected into Caco-2 cells and treated with different concentrations of MTX 
(8 nM, 40 nM, 200 nM, 1000 nM and 5000 nM) or CAR. pRL-TK was used as the 
internal control for the transfection assay.  Luciferase activity was measured according to 
the manufacturer's recommendations. Values are averaged from three independent 

























Figure 5.1.1 System involved in MTX induction of hSULT2A1. 
This figure is the answer of figure 2.1 on page 24. The question marks in figure 2.1.1 
were answered in this figure. The nuclear receptors involved in hSULT2A1 regulation 
are CAR, VDR, PXR, and RXRα. The RXRα functions as a common heterodimer 
parterner and interacts with CAR, VDR, and PXR. The 9-cis- retinoic acid (RA) acts as 
ligand for RXRα. MTX acts as agnist for CAR. The DNA cis-element that interacts with 
nuclear receptor heterodimers located in -183/-173 of hSULT2A1 promoter region, it is 
an IR2 element.
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5.1 System Involved in MTX Induction of hSULT2A1  
Back to our hypothesis in chaper 2, we proposed that the MTX induction of 
hSULTs are mediated through the interaction of nuclear receptors with the DNA cis-
elements located in the proximal promoter region of hSULT genes. As indicated in figure 
5.1.1, we approved our hypothesis through a series experiments. With the endogenous 
induction study, we found MTX can induce hSULTs in both Hep G2 cells and Caco-2 
cells, these inductions were further confirmed by dual luciferase reporter gene assay. 
Then we chose Caco-2 cells as model to investigate the MTX induction mechanism. With 
the cotransfection assay, we found CAR, VDR, and RXRα can up-regulate the 
expression of hSULT2A1, PXR can down-regulate the expression of hSULT2A1. The 
positive role of CAR was further confirmed by the RNA intereference experiment. With 
the promoter deletion, DNA sequence alignment and promoter mutation, we found the 
IR2 element located at -186 to -173 of hSULT2A1 promoter region was the DNA cis-
element responsible for the up-regulation of hSULT2A1. Through EMSA assay and 
super shift assay, we confirmed the interaction of the IR2 element with CAR and RXRα. 
Since we found several nuclear reptors all involved in the regulation of hSULT2A1, we 
tested the cross-talk of these nuclear receptors and we found that CAR, VDR, and PXR 
can all interact with the IR2 element. CAR competed with VDR for the promoter activity 
of hSULT2A1.  PXR repressed the up-regulation of CAR in hSULT2A1 regulation. 
 
5.2 MTX Induction of hSULTs in Hep G2 and Caco-2 Cells 
Human liver and human intestine are the two major organs that are involved in  
drug metabolism. Hep G2 cells derived from a human hepatoblastoma that is free of 
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known hepatotropic viral agents. A wide variety of drug metabolizing enzymes have been 
found to expressed in Hep G2 cells (Javitt 1990; Schmiedlin-Ren, Thummel et al. 2001). 
Caco-2 cells originally derived from a human colon adenocarcinoma and have been 
extensively used over the last twenty years as model for human intestinal cells (Sambuy, 
De Angelis et al. 2005). Since differentiated Caco-2 cells express various cytochrome 
P450 isoforms and phase II enzymes such as UDP-glucuronosyltransferases, SULTs and 
glutathione-S-transferases, this model is also used in the study of drug metabolizing 
enzymes (Meunier, Bourrie et al. 1995). In our study, we found the abundance of 
hSULT2A1 and hSULT1A1 in both Hep G2 and Caco-2 cells are very high, so here we 
use Hep G2 and Caco-2 cell lines as model to investigate the effect of MTX on the 
transcriptional regulation of hSULTs. 
MTX is a drug that is widely used cilnic against cancer and other diseases.  MTX 
and its polyglutamate metabolites are folic acid analogues with inhibitory activity against 
many enzymes in the metabolic pathway of folic acid.  MTX inhibits the production of 
thymidylate, purine, and methionine and leads to accumulation of adenosine (Jandik, 
Kruep et al. 1996).  These actions inhibit cellular proliferation and induce apoptosis.  
Inducers of cytochrome P-450 (CYP) have been reported to enhance MTX-induced 
hepatocytotoxicity (Tsuda, Yamada et al. 1999).  MTX is also reported to slightly down-
regulate some of the CYP genes (Cheung, Lee et al. 1996).  MTX inductions any drug 
metabolizing enzymes are basically unknown.   
Regulations of SULT expression by endogenous molecules (i.e. hormones and 
bile acids) are relatively well documented (Fang, Abdolalipour et al. 2005; Janer, Lavado 
et al. 2005). The biochemical consequences of these regulations are of importance in 
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relation to their physiological processes. There are some reports studying drug or 
xenobiotic induction of SULTs in either animal tissues or cultured human cells (Runge-
Morris 1998; Maiti and Chen 2003; Maiti and Chen 2003). In the present investigation, 
we report that MTX can increase hSULT expression and activity in cultured human cells. 
MTX induced hSULTs in Hep G2 cells and Caco-2 cells differently. After being 
treatment with MTX, the protein and mRNA level of hSULT2A1 (P-PST), hSULT1A3 
(M-PST), hSULT2A1 (DHEA-ST), and hSULT1E1 (EST) in Hep G2 cells were induced; 
hSULT1A3 and hSULT2A1 in Caco-2 cells were induced. Our enzyme assay and 
Western blot (protein level) are in good agreement with RT-PCR result. This clearly 
indicates that MTX induction of hSULTs is at the transcriptional level. We have also 
shown that MTX can induce rat SULTs (Maiti and Chen 2003). Combined with known 
results from publications of other drug metabolizing enzymes, our results support a 
nuclear receptors mediated mechanism for MTX induction of hSULTs.  
  
5.3 Cytotoxicity and Transcriptional Activation of hSULT2A1 in Hep G2 and  
Caco-2 Cells Exposed to MTX 
Through endogenous induction study, we found MTX can induce hSULTs in a 
concentration-dependent manner in both Caco-2 and Hep G2 cells. It is well known that 
high concentrations of MTX can cause cytotoxicity to human cells. We wanted to see if 
MTX induction of hSULTs was caused by the MTX cytotoxicity. We cloned the 
promoter sequence of hSULT2A1 and ligated it into the basic luciferase reporter vector 
so the expression of luciferase was regulated by the hSULT2A1 promoter. We used this 
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reporter vector to test the transcriptional activation of hSULT2A1 by MTX, and we used 
the MTT assay to test the cytotoxicity of MTX to Caco-2 and Hep G2 cells. 
MTX elicited time- and concentration-dependent cytotoxicity to both Hep G2 
cells and Caco-2 cells (figure 4.2.1 and figure 4.2.2), but Caco-2 was more sensitive to 
MTX. Caco-2 cells showed significant cytotoxicity when tread with 0.5 μM MTX for 
only 2 days. In contrast, Hep G2 cells did not show any cytotoxicity until treated with 0.5 
μM MTX for 4 days. This may be because Hep G2 cells express more enzymes involved 
in drug metabolism. Because the human intestine is mainly involved in nutrient 
absorption, the intestine cells have less ability to detoxify exogenous molecules; so even 
when CAco-2 cells are are exposed to low concentrations of MTX for a short time, their 
viability of Caco-2 cells is significantly decreased.   
In our reporter gene assay, Caco-2 cells were more sensitive to MTX treatment 
compared with Hep G2 cells. When the transfected Caco-2 cells were treated with MTX, 
the promoter activity of hSULT2A1 in Caco-2 cells showed time- and concentration- 
dependent induction (figure 3.2.3). In a fixed time (we tested from 12 hours to 48 hours), 
the promoter activity of hSULT2A1 increased when the MTX concentration increased 
from 0.04 μM to 5 μM. After that, when the MTX concentration increased to 12.5 μM, 
the promoter activity decreased. For a fixed concentration of MTX (from 0.04 μM to 12.5 
μM), the promoter activity of hSULT2A1 increased when the exposure time increased. 
Compared with Caco-2 cells, the basic promoter activity of hSULT2A1 increased when 
the MTX incubation time increased. The concentration-dependent induction in Hep G2 
cells was not so obvious. The different induction patterns in Hep G2 and Caco-2 cells 
suggest different cells have different transcription factor expression when applied in 
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different signal transduction pathways, these cells will respond in different ways. The 
MTX concentrations used in reporter gene assay are much higher than the MTX 
concentrations used in the endogenous study. The induction of hSULTs reaches the 
highest level when the MTX concentration is 0.1 μM in the endogenous induction study; 
while in reporter gene assay, the induction reaches the highest level when MTX 
concentration is 5 μM. The reason for this difference may come from the different 
methods. In the reporter gene assay, we transfected as many as 1X1010 copies of reporter 
genes into 1X 105 cells. Undoubtedly, as a consequence, the full induction of hSULT2A1 
promoter activity needs much higher concentration of MTX in the reporter gene assay. 
From the MTT assay results, we know low concentration and short time of MTX 
exposure does not cause any significant cytotoxicity to Caco-2 and Hep G2 cells. When 
the Caco-2 cells were treated with MTX for 2 days, the estimated IC50 (inhibitory 
concentration 50%) was 34 μM. In the induction study, however, 2 days exposure of 0.1 
μM MTX caused the promoter activity of hSULT2A1 to significantly increase. 
Obviously, the induction of hSULT2A1 activity was not caused by the cytotoxicity of 
MTX. In the following MTX induction mechanism studies, we chose the concentration of 
0.1 μM MTX for all experiments. With this concentration, we excluded the possibility 
that MTX induction of hSULT2A1 was caused by its cytotoxicity.  
 
5.4 hSULT2A1 is transcriptionally Regulated by CAR 
Phase I and phase II drug metabolizing enzymes, such as cytochrome P-450 and 
UDP-glucuronosyltransfersase (UGT) are well known to be regulated by endogenous 
hormones as well as by therapeutic drugs and other xenobiotics. SULTs, one of the major 
 90
families of phase II drug metabolizing enzymes, are also well known to be regulated by 
hormones. Xenobiotic induction of SULTs, though, is not well studied (Runge-Morris 
1997; Gaworecki, Rice et al. 2004). Nuclear receptors, which mediate the induction of 
some phase I and phase II enzymes, have recently been shown to mediate the induction of 
SULTs. Reports on the nuclear receptor mediated induction mechanisms of SULTs 
focused primarily on SULT2A1 from different species. An IR0 element in rats and mice 
was proposed to be the DNA binding site for different nuclear receptors in regulation of 
SULT2A1. The nuclear receptors form heterodimers with RXRα. These nuclear 
receptors include  FXR/RXRα (Aste, Cozzi et al. 2001), PXR/RXRα (Duanmu, Locke et 
al. 2002), VDR/RXRα (Echchgadda, Song et al. 2004), and CAR/RXRα (Saini, Sonoda 
et al. 2004). FXR and PXR were also reported to repress basal mSULT2A1 expression 
using FXR-null or PXR-null mice (Kitada, Miyata et al. 2003) and to inhibit vitamin D3 
induction of mSULT2A1 via VDR (Echchgadda, Song et al. 2004). 
In the present study, we have shown that the promoter of hSULT2A1was induced 
by the highly selective hCAR agonist CITCO in Caco-2 cells. Most importantly, we 
found that the widely used clinic anti-folate drug MTX has a high potency to induce 
hSULT2A1 which is similar to CITCO. Our results indicate that hCAR transactivates the 
induction of hSULT2A1. RXRα enhances CAR transactivation of hSULT2A1. This 
agrees with earlier reports on nuclear receptor transactivation of various drug-
metabolizing enzymes. Almost all known nuclear receptors form heterodimers with 
RXRα to transactivate drug metabolizing enzymes. The induction caused by MTX has 
synergistic effect with CAR and RXRα, which suggests MTX can function as an agonist 
of hCAR. The RNA interference experiment further supports the expression of 
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hSULT2A1 was closely related to the expression of hCAR. When the hCAR expression 
vector was transfected into Caco-2 cells, the mRNA levels of both hCAR and hSULT2A1 
were significantly increased, which mean hCAR can mediate the induction of 
hSULT2A1. When the CAR was knocked down by siRNA, the mRNA level of 
hSULT2A1 was also decreased, and this was further confirmed by reporter gene assay 
results. 
Our deletion analysis suggests that the binding site of CAR/RXRα is located 
between -188 to -130 in the 5'-flanking region of hSULT2A1. Sequence alignment result 
(Figure 4.3.4) indicates that the IR0 sequence, which is responsible for transactivation of 
rat and mouse SULT2A1, does not exist in the hSULT2A1 5’-flanking region. Analysis 
of -188 to -130 DNA sequence of hSULT 5’-flanking region revealed an IR2 element. 
Our mutation results (Figure 4.3.5) further show the importance of this IR2 element in the 
transactivation of hSULT2A1 via the CAR/RXRα heterodimer during MTX induction. 
The identified IR2 element in our report agrees with a previous prediction of several 
putative (A/G)G(G/T)TCA nuclear receptor half-site motifs in the 5’-flanking region of 
hSULT2A1 (Duanmu, Locke et al. 2002).  
It is well known that nuclear receptors can bind to a broad range of ligands and 
regulate genes that are involved in drug clearance and disposition. These nuclear 
receptors share parterners, ligands, DNA response elements and target genes. Moreover, 
they influence mutually their relative expression (Chou, Prokova et al. 2003; Kodama, 
Koike et al. 2004). Our results suggest that there are cross-talk between CAR and PXR. 
The cotransfection of PXR can significantly decrease the induction caused by CAR and 
MTX. Our results also show that CAR can enhance the transcriptional activity of 
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hSULT2A1. When the IR2 sequence was mutated, the cotransfection of CAR repressed 
the mutated promoter activity. This suggests that there may be other nuclear receptors 
and DNA binding elements that also involved in transactivation of MTX induction of 
hSULT2A1. The mutation affects the binding of CAR/RXRα heterodimer to the mutated 
IR2 sequence and abolishes the induction of CAR. The cotransfection of extra exogenous 
CAR may compete for limited endogenous RXRα with other nuclear receptors and cause 
a final inhibition effect of the promoter activity. 
In conclusion, our results demonstrate the positive role of hCAR in the regulation 
of hSULT2A1. We identified a CAR/RXRα heterodimer-binding element, IR2. This IR2 
element is different from the reported IR0 element in rat and mouse SULT2A1 gene. The 
relative position of IR2 in the hSULT2A1 gene and IR0 in rat and mouse is very close 
(Figure 4.3.4). These results could explain the differences and similarities between 
hSULT2A1 induction and rat and mouse SULT2A1 induction. Further characterization of 
the role of MTX involved in hSULT2A1 regulation may be of considerable therapeutic 
significance. We are currently investigating the role of other nuclear receptors like PXR, 
and VDR in basal and regulated SULT2A1 expression in Hep G2 and Caco-2 cells. These 
studies should provide insights into the cross-talk between different nuclear receptors in 
hSULT2A1 transcriptional regulation. 
 
5.5 Cross-talk among CAR, PXR, and VDR in the Transcriptional Regulation of 
hSULT2A1 
hSULT2A1 is an important cytosolic enzyme in human liver and human intestine 
that catalyzes the sulfation of steroid hormones such as DHEA and xenobiotic alcohols. 
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The expression of rSULT2A1 has known to be regulated by several nuclear receptors 
through the same DNA cis-element located in the proximal promoter region of 
rSULT2A1. Song first reported that the primary bile acid chenodeoxycholic acid (CDCA) 
acts as a regulator of rSULT2A1 through the farnesoid X receptor (FXR) by binding to 
an IR0 element located at -193bp to -169bp of the promoter (Song, Echchgadda et al. 
2001). Other reports demonstrated that both PXR and VDR can bind to the same DNA 
response element and up-regulate the expression of rSULT2A1 (Sonoda, Xie et al. 2002; 
Echchgadda, Song et al. 2004). In this case, PXR and FXR compete with VDR for the 
same IR0 element. It has also been reported that both steridogenic factor 1 (SF1) and 
estrogen-related receptor alpha (ERRα) bind to the same DNA response element and 
regulate hSULT2A1 expression (Saner, Suzuki et al. 2005; Seely, Amigh et al. 2005). 
Recently, the vitamin D receptor (VDR) was reported to interact  with hSULT2A1 
promoter sequence through the same DNA cis-element as we reported here (Song, 
Echchgadda et al. 2005). In our experiments, we found both CAR and VDR can up-
regulate the expression of hSULT2A1, PXR inhibit the expression of hSULT2A1. 
Although all CAR, PXR, and VDR are involved in the transcriptional regulation 
of hSULT2A1, different nuclear receptors have different effects. CAR and VDR induce 
the expression of hSULT2A1; PXR represses the expression of hSULT2A1. All three 
nuclear receptors can bind to the same IR2 element located in the proximal promoter 
region of hSULT2A1. The IR2 element functions as positive DNA response element for 
both CAR and VDR; but for PXR, it functions as negative DNA response element. After 
the IR2 sequence was mutated, the basic promoter activity decreased.This indicates that 
this IR2 sequence was very important for the maintenance of the full activity of the 
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promoter. All three nuclear receptors show inhibition effect on the mutated hSULT2A1 
promoter activity when cotransfected with the mutated luciferase promoter vector. This 
suggests the complexity of the signal transduction pathway of hSULT2A1. The inhibition 
of nuclear receptors may be because they can not bind to the mutated IR2 sequence, they 
start to compete for the limited amount of common heterodimer parterner such as RXRα. 
The exhaust of RXRα causes other nuclear receptors or transcription factors can not bind 
to their regulatory sequence and perform their function. As a result, the promoter activity 
is further decreased. 
CAR activates MTX induction of hSUTL2A1 whereas PXR inhibits this 
induction. This suggests PXR may compete with CAR for binding to the IR2 element. 
PXR may also transactivate other drug metabolizing enzymes when appropriate inducers 
are present. The hormonal and metabolic milieu of the cells determined which of the 
competing nuclear receptors will assume a dominant role in regulating hSULT2A1 
expression. This is supported by our mutated IR2 results (Figure 3.4.5), which suggest 
that there may be other nuclear receptors and DNA binding elements that can also 
transactivate MTX induction of hSULT2A1. In the case of MTX induction of 
hSULT2A1, CAR is at least one nuclear receptor responsible for the stimulation of gene 
expression through the IR2 element. Our results also agree with recent reports that CAR 
transactivates hSULT2A1 expression (Assem, Schuetz et al. 2004; Kim, Shigenaga et al. 
2004; Saini, Sonoda et al. 2004) and PXR inhibits CAR mediated induction (Kitada, 
Miyata et al. 2003; Echchgadda, Song et al. 2004) 
VDR competes with CAR in the up-regulation of hSULT2A1 (figure 3.4.7). This 
suggests that the two nuclear receptors may share common DNA response elements and 
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heterodimer parterners such as RXRα. Because both nuclear receptors can bind to the 
same DNA cis-element, their relative concentrations determine their final effect. In the 
competition experiments, CAR is more sensitive than VDR, when the CAR amount is 
only 5 ng, CAR can repress the VD3 induction of hSULT2A1 to the control level. Higher 
CAR concentration increases the basal hSULT2A1 promoter activity and MTX induction 
activity, but VD3 induction activity through VDR was inhibited by CAR. 
In summary, our results have shown that there is nuclear receptor cross-talks in 
the regulation of hSULT2A1. Our data show that MTX induces hSULT2A1 in a time-
dependent manner in both Caco-2 and Hep G2 cells. All three nuclear receptors: CAR, 
PXR, and VDR were found to participate in the MTX transcriptional regulation of 
hSULT2A1. These nuclear receptors compete with each other for common DNA cis-
element and heterodimer parterners such as RXRα. The final effect of these nuclear 
receptors to hSULT2A1 depends on their concentrations, cell types and physiological 
conditions. Understanding the mechanism of MTX induction of hSULT2A1 may 
contribute to better understanding of drug resistance, drug efficiency, drug-drug 
interaction, and the development of better drug treatments. 
 
5.6 Summary 
hSULT2A1 is a cytosolic sulfotransferase which occurs predominantly in human 
liver, adrenal and intestine. The activity of this enzyme is not gender-dependent but 
shows highly dynamic expression throughout the lifespan (Saner, Suzuki et al. 2005). 
The hSULT2A1 substrates includes physiological hydroxysteroids such as 
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dehydroepiandrosterone, pregnenolone, estrogen, pregnenolone, bile acid and xenobiotic 
alcohols (Chatterjee, Song et al. 1994; Song, Echchgadda et al. 2001; Strott 2002). 
Besides endogenous molecules, xenobiotics and therapeutic drugs such as 
tamoxifen were also reported to be sulfated by hSULT2A1 (Chen, Yin et al. 2002; 
Falany, Pilloff et al. 2005). The regulation of hSULT2A1 has been reported to be 
mediated by several transcription factors including steroidogenic factor 1 (SF1), GATA-
6, peroxisome proliferator-activated receptor alpha (PPARα), estrogen-related receptor 
alpha (ERRα),  essential Role of the CAAT/Enhancer Binding Protein alpha and  vitamin 
D receptor (VDR) (Fang, Strom et al. 2005; Saner, Suzuki et al. 2005; Seely, Amigh et al. 
2005; Song, Echchgadda et al. 2005). To investigate the molecular mechanism involved 
in MTX induction of hSULT2A1, we cloned the 5’ flanking region of hSULT2A1 
promoter sequence and ligated it to the luciferase reporter vector (pGL3-Basic, Promega). 
Step wise deletion and mutation studies show the IR2 sequence located in the proximal 
promoter region of hSULT2A1 is very important in hSULT2A1 regulation. Through 
cotransfection experiments, we found CAR can significantly induce the promoter activity 
of hSULT2A1. With the presence of MTX, CAR has synergistic effect with MTX and 
can further increase the activity of hSULT2A1. Further studies include siRNA and real-
time PCR confirmed the positive role of CAR in the up-regulation of hSULT2A1. DNA 
gel shift assay and super shift assay results suggest CAR can heterodimerize with RXRα 
and bind to the IR2 DNA cis-element. Contrast to the up-regulation of CAR, PXR can 
suppress the promoter activity of hSUlT2A1. PXR serves as an antagonist of CAR. The 
cotransfection of PXR can decrease the induction of hSULT2A1 caused by both MTX 
and CAR. The nuclear receptor VDR, however, shows a different effect on CAR 
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induction, by binding to its ligand Vitamin D3 (VD3), VDR can compete with CAR for 
the promoter activity of hSULT2A1. Our super shift data show both CAR and RXRα can 
bind to the IR2 element. This is very similar to the endogenous hormone regulation of 
other drug metabolizing enzymes; where the nuclear receptors share parterners, DNA 
response elements and target gene. The cross-talk between different nuclear receptors 
determines the net activity of MTX treatment toward hSULT2A1 expression. 
 
5.7 Significance of MTX Induction Mechanism of hSULTs 
Our research on the mechanism of MTX induction of hSULT2A1 provides novel 
information not only on therapeutic drug regulation of hSULT, but also on the nuclear 
receptors involved in signaling transduction network of drug metabolism enzymes. 
Because CAR was involved in the gene regulation of a large overlapping set of genes 
including cytochrome P450s, multidrug resistance proteins, and SULTs (Kast, Goodwin 
et al. 2002; Ferguson, Chen et al. 2005; Xu, Li et al. 2005), the net therapeutic effect of 
MTX needs to be fully recognized. Our study provides important insights into the 
influence of therapeutic drugs on human drug metabolism enzymes and the research is 
expected to make significant contributions to understanding of carcinogen bioactivation, 
cancer prevention, drug resistance, drug design and development, drug-drug interactions, 






1. MTX can induce the main four families of hSULTs (hSULT1A1, hSULT1A3, 
hSULT2A1 and hSULT1E1) at both mRNA and protein level in Hep G2 cells in a 
concentration-dependent manner. 
2. MTX can induce hSULT1A3 and hSULT2A1 in both mRNA and protein level in 
Caco-2 cells in a concentraion-dependent manner. 
3. MTX induces hSULT2A1 at both mRNA and protein level in both Caco-2 and 
Hep G2 cells in a time-dependent manner. 
4. The cytotoxicity of MTX to Hep G2 and Caco-2 cells were tested, we approved 
the induction of hSULTs caused by MTX was not come from its cytotoxicity. 
5. High dose of folic acid can inhibit the MTX induction of hSULTs at both mRNA 
and protein level in Hep G2 cells. 
6. The promoter sequence of hSULT2A1 was cloned from Hep G2 genomic DNA 
and has promoter activity. 
7. The promoter sequence of hSULT1A1 was cloned from Hep G2 genomic DNA. 
This promoter has two alternative sequences. We cloned P1, P2 and the full 
sequence (P). All three promoter sequences have biological function. The 
promoter activity of P1 is almost 10 fold higher than P2 and P.
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8. All three promoter sequences: P1, P2 and P can be up-regulated by MTX. 
9. MTX has no influence on the three promoter sequences with the reporter gene 
assay in Hep G2 cells.   
10. MTX induces hSULT2A1 in Caco-2 cells in a time- and concentration-dependent 
manner with the reporter gene assay, which is consistent with the endogenous 
study. 
11. CAR can induce the promoter activity of hSULT2A1 in both Caco-2 and Hep G2 
cells in a concentration-dependent manner 
12. RXRα can induce the promoter activity of hSULT2A1 in Caco-2 cells 
13. CAR can induce the endogenous mRNA level of hSULT2A1. Knock down the 
CAR through siRNA, can abolish the up-regulation of hSULT2A1 caused by 
CAR 
14. The IR2 element located in the proximal promoter region of hSULT2A1 is very 
important in the regulation of hSULT2A1. 
15. PXR can inhibit the promoter activity of hSULT2A1 in both Caco-2 and Hep G2 
cells in a concentration-dependent manner 
16. VDR can induce the promoter activity of hSULT2A1 in both Caco-2 and Hep G2 
cells. 
17. EMSA and super shift assay show CAR and RXRα can bind to the IR2 element 
18. PXR can repress the induction of hSULT2A1 mediated by MTX and CAR in 
Caco-2 cells 
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